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ABSTRACT

In vivo assessment of the effects of inorganic arsenic, arsenite (As+3), on the bone
marrow (BM) immune progenitor cells in mice showed that 300 parts per billion (ppb) As+3
given over 30 days in drinking water, produced a decrease in total BM cells recovered and
suppressed the lymphoid (pre-B) but not the myeloid (GM) progenitor cells colony forming
units (CFUs). 75 and 300 ppb As+3 also suppressed spleen T-dependent antibody responses.
There was no shift in the general markers of early hematopoietic stem cells, CD34 and
CD38, or the mesenchymal stem cells, CD105, in the BM. Splenic CD45+ B cells were
unaltered. In vitro studies of three inorganic arsenic species and metabolites, As+3, As+5, and
monomethylarsonous acid (MMA+3) at low concentrations (5 - 500 nM) determined that As+3
selectively suppressed the lymphoid progenitors at 50 and 500 nM concentrations. MMA+3
(starting at 5nM) also demonstrated concentration-dependent lymphoid toxicity.
Dibenzo[def, p]chrysene (DBC) was also suppressive to the BM in vivo, producing
about 90% suppression of the lymphoid progenitors at 10 mg/kg given orally over 5 days in
v

pill forms. At much lower (1 mg/kg), 5 day oral cumulative dose, DBC slightly decreased
BM cell recovery, resulting in suppression of CFU-B but not CFU-GM.
As environmental co-contaminants, As+3 and DBC co-exposure could easily occur.
Results from this research suggest that low dose DBC interacts with established no-effect
doses (19 and 75 ppb) of As+3 to produce more BM lymphoid suppression that does not
necessarily increase with dose in vivo. In vitro studies show similar pattern for As+3-DBC
interactions, occurring at lower (0.5 nM), but not at the higher (5 nM) concentration of As+3.
The selective targeting of lymphoid progenitors by low dose As+3 and DBC suggest
the involvement of an exclusive signaling pathway. B cells require IL-7 signaling for normal
development. This study has uncovered the MMA+3 interference with phosphorylation of
STAT5 in the IL-7 signaling pathway, and with the induction of PAX5 gene which is
required to maintain commitment to the B-lineage.
In summary, these studies contribute to our understanding of BM toxicity by
environmentally relevant levels of arsenite.
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CHAPTER 1

GENERAL INTRODUCTION

1

GENERAL INTRODUCTION
The Bone Marrow, Hematopoiesis, Host Immunity and the Environment
Bone marrow (BM), the mass of soft tissue found in the inner core of axial and long
bones, is a primary lymphoid and hematopoietic organ (Travlos, 2006). Having various
structural components with specialized functions, the BM tissue consists mainly of the red
marrow (red- colored hematopoietic tissue) and yellow marrow (yellow-colored adipose
tissue). At birth, the BM is mostly red marrow and this continues to be replaced by yellow
marrow through adulthood (Moore and Dawson, 1990). The function of hematopoietic tissue
is to produce the immune cells by the process of hematopoiesis. This tissue is made up of
hematopoietic stem cells (HSCs), stem cell derivatives including the immune cells and blood,
and stromal cells which are not directly involved in the production of blood and immune
cells. The stromal cells, however, provide the microenvironment necessary for maintenance
and self-renewal of the stem cells (Gasper, 2000), and also produce vital growth factors,
such as cytokines, which are required for lineage commitment, differentiation, maturation,
viability and proliferation of the immune cells (Chen et al., 2001).
All immune cells originate from one pluripotent hematopoietic stem cell stage and
then commit to specific lineages by responding to the lineage-appropriate growth factors.
While in the BM, immune cell precursors express receptors for signaling the lineage-specific
growth factors. From the pluripotent hematopoietic stem cells, the common myeloid
progenitors (CMPs) and common lymphoid progenitors (CLPs), with their receptors, respond
(in addition to other common factors) specifically to granulocyte monocyte cell stimulating
factor (GM-CSF) and interleukin 7 (IL-7), respectively. They then undergo further
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Figure 1.1. The Bone marrow and Hematopoiesis.

3

differentiation to produce the mature cells that are released into the blood and periphery
(Figure 1.1). The BM has extensive vascularity, thus the red and yellow marrow have rich
blood supply and could easily be exposed to endogenous and exogenous compounds that are
transported in the blood. Studies have shown that the BM hematopoietic tissue and immune
cell precursors can be very sensitive to substances that are carried in the blood. The immune
cells have the primary responsibility of disease prevention and their differentiation through
the lymphoid and myeloid lineages in the BM (Fig 1.1) could suffer the initial impact from
environmental pollutants prior to disease manifestation. The myeloid and lymphoid
progenitors produce the cells responsible for adaptive and innate immune responses
respectively.
Lymphopoiesis and IL-7 Signaling
To understand the potential effects of environmental agents on adaptive and innate
immunity, it is important to understand how the immune cells develop in the BM. The
common lymphoid progenitors become differentiated under the specific influence of BM
growth factors. For myeloid cells, GM-CSF is required for development, whereas lymphoid
pre-B and pre-T cells develop in response to IL-7 (Figure 1. 2). IL-7 is a major cytokine of
the immune system. It is vital for normal development of B cells and T cells, and is produced
by the stromal cells of the BM and various other tissues, but lacking in normal lymphocytes
(Golden-Mason et al., 2001; Gutierrez-Ramos et al., 1992; Sakata et al, 1990, Wiles, et al.,
1992). In the various IL-7- producing tissues, it is known to bind to the molecules of
extracellular matrix such as fibronectin and glycosaminoglycan and is therefore readily
available in the microenvironment for signaling (Ariel et al., 1997). IL-7 receptors consist of
the IL-7Rα (CD127) which is specific for IL-7, and IL-7Rγc chain that is shared by other

4

cytokines including IL-2, IL-4, IL-9, IL-15 and IL-21. Immature B cells express both
components of IL-7R. When the ligand binds to CD127, it elicits a signaling response.
Studies show that deletion of IL-7 inhibits the differentiation from pro-B cells to the pre-B
cell stage (von Freeden-Jeffry et al., 1995), whereas deletion of the receptor, CD127, results
in the inhibition of differentiation from the CLPs to the pre-pro B stage (Peschon et al.,
1994). For signaling, IL-7 ligand binds to the CD127 of the IL-7- responsive immature
lymphoid cells, and results to the dimerization of CD127 and IL-7Rγc chain. The Janus
kinase 3 (JAK3) which is constitutively associated with the tyrosine of IL-7Rγc chain,
phosphorylates the CD127-associated Janus kinase 1 (JAK1). It is JAK1 that recruits other
intracellular signaling molecules, including the transcription factor, signal transduction
activator of transcription 5 (STAT5), phosphotidylinositol 3 kinase (P13K), and Src kinase.
CD127 does not have tyrosine kinase activity. Activated STAT5 molecules dimerize and
translocate to the nucleus to regulate the transcription of downstream lymphoid developmentassociated genes (Figure 1.2).
Individual evaluation of the myeloid and lymphoid progenitor cell responses in the
BM could therefore reveal an aspect of the immune system that may be compromised from
environmental pollutant exposure. Alterations in BM differentiation of lymphoid and
myeloid cells will likely adversely affect host immunity, resistance to infections, and could
lead to cancer.

5

Figure 1.2. Scheme for IL-7 signaling in B cells
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Environmental Chemicals Alter Host Immunity and BM Development
There is evidence that many environmental chemicals and drugs alter BM
hematopoietic activity (Irons et al, 1985). Certain drugs, malnutrition, alcohol, and
chemotherapy are known to suppress the BM (Cunha, et al., 2013, Fantuzzi and Faggioni,
2000; Scharf and Aul, 1988; Sommadossi and Carlisle, 1987). Exposure to pollutants such as
benzene and PAHs (including benzo[a]pyrene, dimethylbenz[a]anthracene (DMBA)), or
complex mixture of pollutants like cigarette smoke which contain PAHs, As+3 and other
chemicals have been shown to produce bone marrow toxicity that manifest as alteration in
peripheral blood cell populations (Burchiel et al., 1987; Galvan et al., 2003, 2005: Heidel et
al., 1998; Irons, 1985; Page et al., 2003).
Polycyclic Aromatic Hydrocarbons (PAHs) and Immunotoxicity
PAHs are a class of compounds containing 2 or more benzene rings. They all differ in
size, structure, and toxicity. The smaller size PAHs are more prevalent as they are formed at
lower temperatures (300-650oC) than the large PAHs which require much higher
temperatures to produce. PAHs have also been detected in barbeque grilled foods.
PAHs may leach into drinking water supplies, settle on the ground, and/or circulate in
the air when they are released by activities such as forest fires, coal burning, and cigarette
smoking. Some PAHs are known carcinogens, and as with arsenic, humans, mammals,
plants, and aquatic life are exposed to PAHs. The average level of PAHs in urban drinking
water supplies is in the range of 0.1-23 ng/L (Harvey et al., 1997). PAHs in the environment
have been shown to produce BM toxicity through several mechanisms such as induction of
pre B cell apoptosis due to the activation of caspases, interference with p53 signaling, and
aryl hydrocarbon receptor (AHR) with cytochrome p450 1 (CYP1) enzymes induction.
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(Heidel et al. 1998, 1999, 2000; Galvan et al., 2003, 2006; Page et al., 2003; N’jai et al,
2010) and systemic immunotoxicity (Burchiel et al., 2005; White Jr. et al., 1985). Our
laboratory has shown that 7,12-dimethylbenz(a)anthracene (DMBA) produces
immunotoxicity via the formation and binding of a DMBA-diol-epoxide to DNA, leading to
the activation of ATM/ATR and p53 pathways (Gao et al., 2005, 2007, 2008).
Although DMBA has been found to suppress pre-B cell formation, in mouse BM, its
mechanism of action has not been well-defined.
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This study focuses on dibenzo[def,p]chrysene (DBC, also known as
dibenzo[a,l]pyrene (DB[a,l]P)) as the PAH of interest because it is an important
environmental PAH which occurs in wood smoke or smoky coal and is released into the air.
In the United States, the typical range for few carcinogenic PAHs in the air is 0.1-1 ng/ m3
(Menichini, 1992). High levels (about 5 ng/m3) of DBC was detected in the indoor air in
Xuan Wei homes in China, an area that also has very high incidence of lung cancer mortality
(Mumford et al., 1995). DBC has not been previously studied for immunotoxicity on BM.
However, our lab has recently shown that it is very immunotoxic to spleen cells (Lauer et al.,
2013) and it is also known to be a potent carcinogen (Buters et al., 2002: Luch et al., 1998).
DBC is a very large molecule consisting of six fused benzene rings (Fig 1.3), with an overall
structure that is related to its toxicity in tissues. Its occurrence in nature is very limited due to
its large size and the temperature requirement for its formation. DBC is thought to be the
most potent carcinogenic PAH (Cavalieri et al., 1991).
Generally, it has been shown that long term or chronic exposures to PAHs produce decrease
in immune function as measured by various immune parameters as shown in (Table 1.1). The
suppression of humoral immune responses in mice (No. 2, Table 1.1) is supported by the
observed decrease in immunoglobulin levels seen in PAH-exposed coke oven workers (No. 1
in Table 1.1). The DMBA –induced apoptosis in pre B cells is also suggestive of PAH
toxicity to developing immune progenitors.
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Table 1.1: Evidence for PAH immunosuppression
Evidence/model
1.

Parameter measured
Concentrations of
Immunoglobulins
G, A, M, and E

Decreased humoral immunity in PAH exposed coke plant workers/ Human

Suppressed humoral immunity in mice
2.
exposed to various PAHs/ Mice
Increased B cell death in mice BM
3. following exposure to DMBA/ Mice- in
vitro, cell line
Alteration in blood monocyte functional
4 differentiation and maturation in PAHexposed PBMC/ Human
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Reference
Szczeklik et al.,
(1994).

Antibody-forming cell
response to sheep
erythrocytes

White et al.,
(1985).

B cell apoptosis

Mann et al.,
(1999).

Dendritic cell
markers:CD1a, CD40, and
CD80

Laupeze et al.,
(2002).

DBC Biotransformation and Toxicity
Studies indicate that DBC metabolism is catalyzed by two enzymes: Cytochrome P450 1B1
(CYP1B1) and microsomal Epoxide Hydrolase (mEH) (Amin et al., 1995; Buters et al.,
2002; Chen et al., 2012; Crowell et al., 2014; Luch et al., 1998; Ralston et al., 1994), and
sometimes by peroxidases (Cavalieri et al., 1991), (Figure 1.4). The action of CYP1B1 and
Epoxide Hydrolase on DBC produces DBC-dihydrodiol which could be further oxidized in
the presence of CYP1B1 to DBC-dihydrodiol epoxide (DBCDE), known to bind covalently
to DNA resulting in DNA adduct formation, the genotoxicity property of DBC. DBCdihydrodiol could also be reduced to catechol by the enzyme, aldoaketoreductase (AKR), for
further breakdown to DBC-quinones (Courter et al., 2007). The formation of quinones is
associated with redox cycling and generation of reactive oxygen species (ROS) with resultant
oxidative stress. Activation of DBC by peroxidases result in the formation of a radical cation
which forms depurinating DBC-dG or dA adducts on DNA. Exposure to DBC has been
associated with immunosuppression, hematotoxicity, and carcinogenesis (Harvey et al.,
1997; Li et al., 2010; N’jai et al., 2010).
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Figure 1.4. Proposed pathways for the biotransformation of DBC
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Arsenic exposure compromises immunity
There is sufficient evidence that arsenic exposure causes immune dysfunction in mice and
humans. Epidemiological studies reveal the association of arsenic exposure to various
cancers and many other diseases including heart disease (Moon et al., 2013), diabetes (Khan,
et al., 2011) and recurrent infections. Gradual erosion of the immune system in long term or
chronic exposures to arsenite could also play a role in determining susceptibility to these
diseases. Measurement of some immune parameters during arsenic exposure (Table 1.2),
show the involvement of the immune system in arsenic association to diseases. Some studies
on human immune suppression caused by arsenite exposure focus on gestational exposures,
and data show that decreased immune cell counts, recurrent infections, and developmental
abnormalities of peripheral lymphoid organs are among the manifestations of As+3 exposure.
(No. 2, 4, and 6. in Table1.2). In adult human exposures, parameters of innate and adaptive
immune responses are also shown to be altered. Mice showed alteration in the innate immune
parameters, peripheral blood counts, increased viral titer which is an indication of reduced
humoral immune responses, and increased morbidity.
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Table 1.2: Evidence for As+3 immunosuppression

1.

2.

3.

4.

5.

6.

Evidence/model/location
100 ppb As+3 during infection associated
with higher influenza virus titer, and
alteration of neutrophil and macrophage
counts/ Mice/ USA
Decreased CD3+ T cells in placenta
following in utero As+3 exposure/ Human
fetus/ Bangladesh
Altered expression of T lymphocyte
immune response genes in humans exposed
to >50 ppb As+3 /Adult human/ USA
Increased Upper and lower respiratory
infections, and total number of infections in
infants following in utero exposure to As+3/
Human fetus/ USA
As+3 exposure correlates with respiratory
complications, elevated immunoglobulins,
decreased WBC counts with low neutrophil
and high lymphocyte count/ Adult human/
Bangladesh
Impairment of infant thymic development
following in utero exposure to As+3/ Human
fetus/ Bangladesh
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Parameter measured
Viral titer, peripheral
blood counts.
Concentration of
maternal urinary As+3
at GW 8 and GW 30
Gene expression in
peripheral blood
lymphocytes by
affymetrix microarray
Maternal urinary As+3
concentration, total
number of infections
and infection severity

Reference
Kozul et al.,
(2009).
Ahmed et
al., (2010).
Andrew et
al., (2008).

Farzan et
al., (2013).

Serum
immunoglobulins,
WBC count and
differential,

Islam et al.,
(2007).

Infant thymic size by
sonography, maternal
urine and breast milk
immune marker, As+3
concentration, infant
morbidity

Raqib et al.,
(2009).

Arsenic Metabolism, Speciation and Toxicity
Arsenic occurs as organic and inorganic species. The inorganic arsenic is harmful due
to its ability to bind to sulfhydryl-containing compounds in the body. Biotransformation of
inorganic arsenic is catalyzed by the enzyme arsenite methyltransferase (AS3MT), also
known as CYT19. The enzyme is a 42 kD protein that catalyzes the methylation of inorganic
arsenic to various trivalent and pentavalent methylated species (Aposhian et al., 2000;
Thomas et al., 2004), using S-adenosylmethionine (SAM) from folic acid metabolism as the
methyl group donor (Gamble et al., 2007) in the presence of glutathione (Fig 1. 5). The
different species of inorganic arsenic differ in levels of toxicity (Styblo et al., 2000; Drobna
et al., 2009). Humans can be directly exposed to two forms of inorganic arsenic: the trivalent
arsenic (As+3) and the pentavalent arsenic (As+5). The pentavalent arsenic is found to be less
toxic than the trivalent arsenic, but it is converted to the trivalent arsenite by arsenate
reductase in the presence of inosine and lipoic acid. This is the first and only step in arsenic
biotransformation that does not involve a methyltransferase. The methylation of trivalent
arsenic to monomethylarsonous acid (MMA+3) is known to be the rate limiting step in arsenic
biotransformation.
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Figure 1.5. Biotransformation of arsenate and arsenite in mammals. AS3MT, Arsenite
methyltranserase; SAM, S-adenosylmethionine; SAHC, S-adenosylhomocysteine.
Structures in red box were evaluated in vitro in mice primary BM cells and 2E8 cell line
in current study.
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Arsenic and PAH Individual and Combined Exposures
Arsenite and PAHs are among the most ubiquitous environmental pollutants
worldwide and they are also ranked among the top 10 in the most recent priority list for toxic
substances compiled by the U. S. Agency for Toxic Substances and Disease Registry
(ATSDR), 2013. As+3 has been implicated in the enhancement of the genotoxicity or
mutagenicity of carcinogens, including PAHs and ultraviolet radiation, by inhibiting DNA
repair (Chiang and Tsou, 2009; Wang et al., 2013).
Arsenic occurs naturally in the air, soil, and water. It is a threat to human health
globally and is associated with numerous diseases. Due to its presence in the soil and water,
arsenic is absorbed by plants and food crops (Carey et al., 2010; Zhao, 2012). Rice is known
to be the major source of arsenic in diets as rice products are contained in many processed
foods including fruit juices and baby formula (Davis et al., 2012), as reported in the United
States Consumer Reports (Nov. 2012). Environmental regulations exist for arsenic in
drinking water but not in food, in the United States (US). In this case, the Environmental
Protection Agency (EPA) set a maximum contaminant level (MCL) for As+3 in drinking
water as 10 ppb. Despite this, some people in the US continue to rely on private unregulated
wells for drinking water supply and are thus exposed to dangerous levels of arsenic (Nielson
et al., 2010). Given the pervading nature of arsenic and without regulation for arsenic levels
in food, it is very challenging to control the level of arsenic exposure. Due to the uses of
arsenic in the past and present, there has been intentional (for example, treatment of acute
promyelocytic leukemia, APL) and unintentional exposures to As+3. The lethal dose of As+3
is about 1-3 mg/kg (ATSDR, 2007).
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Exposures to environmental chemicals seldom occur in isolation as many of them are
found together naturally. The uptake of trace elements together with PAHs by fruits and
vegetables from contaminated soils has been reported (Samsɵe-Petersen et al., 2002). Arsenic
and other pollutants like lead, are also known to be absorbed by vegetable crops that are
grown on soils which have been contaminated by pesticides made with lead and arsenic
(McBride, 2013). Elevated levels of arsenic, uranium, and selenium have been found to occur
in Central Oklahoma Aquifer, which is a major source of drinking water for Central
Oklahoma (USGS, 1998). The occurrence of arsenic in drinking water and food crops, and
the presence of detectable levels of PAHs in cooked and uncooked food (Philip, 1999) is a
public health concern. Table 1.3 provides some evidence for As+3 and PAH
immunosuppressive interaction. Both the known detrimental effects of arsenite such as
decrease in humoral immune responses, and the genotoxicity property of PAHs are modified
in combined exposures to both chemicals.
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Table 1.3: Evidence for As+3 and PAH immunosuppressive interaction

1.

2.

3.

4.

Evidence/model
Synergistic suppression of
immune responses in murine
spleen cells exposed to low
dose As+3 and PAHs/ Mice
Increased BaP genotoxicity in
As+3- exposed Hepa-1 cells
and c37 cells/ cell lines
Increased risk of lung cancer
due to occupational exposure
to As+3 and active
smoking/Human/ Bangladesh
Risk of As+3-induced skin
lesions modified by tobacco
smoking/ Human/
Bangladesh

Parameter measured

Reference

T-dependent antibody
responses

Li et al., (2010).

BaP-DNA adduct formation

Maier et al., (2002).

Examination of previous data
on individuals
exposures in relation to lung
cancer risk
Baseline data from study
subjects, information on well
As+3 concentration, and
history of well use.
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Hertz-Piccioto et al.,
(1992).
Chen et al., (2006);
Melkonian et al.,
(2010).

As+3 and PAH Interactions and Overall Goal of these Studies
The purpose of the present work is to determine whether PAHs, in this case DBC,
interacts with As+3 in vivo and in vitro in mice models of BM development. These studies
were proposed based on the knowledge that DMBA produces immunotoxicity in murine BM
and spleen cells via genotoxicity due to the formation of DMBA-DE protein adducts and
also that low doses of PAHs (DMBA, DBC, and BaP-diol) in combination with As+3 resulted
in synergistic suppression of T-dependent antibody responses in murine spleen cells (Li et
al., 2010).
The mechanism for synergistic immunosuppression has not been determined, but it is
logical that inhibition of DNA repair pathways might be important. As+3 was known to
inhibit DNA repair in many cells (Hartwig et al., 2003; Wang et al., 2013; Zhou et al., 2011).
Inhibiting the repair of immune cell DNA adducts and strand breaks could result in
immunosuppression. Based on this idea, it was postulated that low dose As+3 and PAH may
produce synergistic immunosuppression of lymphoid cells in the BM. Thus, we proposed
Specific Aims to look at the BM toxicity of low dose As+3 alone, and in combination with
DBC, and then to investigate potential mechanisms.

21

Hypothesis and Specific Aims

The overall hypothesis to be tested is that combined exposures to arsenite (As+3) and
dibenzo[def,p]chrysene (DBC), a polycyclic aromatic hydrocarbon (PAH), at
environmentally relevant levels targets the immune progenitor cells in the bone marrow
(BM) resulting in suppression of immune responses.
Specific Aims

Specific Aim 1: To determine whether oral exposure to environmentally relevant levels of
arsenite leads to the suppression of immune progenitor cell responses in the bone marrow.
The hypothesis to be tested is that As+3 suppresses the lymphoid and myeloid progenitor cells
in the BM.

Specific Aim 2: To examine potential interactions between arsenite and DBC in BM immune
cells suppression. The hypothesis is that mice simultaneously exposed to no-effect levels of
arsenite and DBC orally, will show BM suppression due to the combined exposure.

Specific Aim 3: Based on findings obtained in Aim 1, we now hypothesize that IL-7
signaling pathways are selectively targeted by As+3 and MMA+3 in murine BM immune cells
in vitro. The hypothesis to be tested is that As+3 and MMA+3 disrupts the cytokine signaling
involved in the lymphoid lineage-specific differentiation of mouse bone marrow cells,
leading to immunosuppression.
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Figure 1.6. The Premise for Current Study
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Rationale
All immune cells originate in the BM through the process of hematopoiesis (Figure
1.1). The myeloid and lymphoid progenitor cells together are responsible for all immune
defenses, thus, individual evaluation of the myeloid and lymphoid progenitor cell responses
in the BM may reveal an aspect of the immune system that may be compromised from low
level arsenite and DBC individual and combined physiological exposures. The selective
targeting of the lymphoid progenitors over myeloid progenitors in the BM by As+3 could
utilize the lymphoid lineage-specific signaling in the BM.

Animal Model, Primary Cells and Cell Line; As+3 and DBC Doses and Concentrations;
Experimental Design
Based on previous relevant studies, C57BL6/J male mice were used for the in vivo
studies. Mice were fed environmentally relevant levels (0-300 ppb) of As+3 orally, via
drinking water for 30 days to mimic long-term exposure. The As+3 doses were chosen after
dose- range studies in order to establish maximum no-effect dose as to determine any
interaction with DBC where applicable. DBC (0- 10 mg/kg, 5-day cumulative dose) was also
administered orally in pill forms to arsenite- exposed (during the last 5 days of exposure) and
unexposed mice. Primary BM cells from mice were exposed to the three inorganic arsenic
species: As+5, As+3, and MMA+3 in vitro (at low levels, 0-500 nM) in order to determine
which species was responsible for observed toxicity.
For the in vivo and in vitro studies, the pre-B and granulocyte-monocyte colony
forming unit (CFU-B and CFU-GM respectively) assays were used as indicators of the bone
marrow lymphoid and myeloid responses to immunotoxicity from the chemical exposures
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and treatments. The IL-7 dependent mouse pre-B cell line, 2E8 cells (Ishihara, et al 1991)
was used to elucidate the mechanism for the observed selective lymphoid toxicity. Because
2E8 cells were normally grown in 1 ng/ml mouse IL-7, they were starved of IL-7 overnight
while in treatment media so that signaling could be stimulated and analyzed by
immunoblotting, flow cytometry, or PCR after reintroduction and incubation with 10 ng/ml
mIL-7 for 30 minutes.
The rationale for using the IL-7-dependent mouse pre-B cell line, 2E8, is that the BM
cell population is highly heterogeneous and the progenitor cells constitute less than 1% of
total BM cells. Thus, to obtain a pure pre-B cell population in large quantities for this study,
the use of 2E8 cells as the in vitro model was necessary. The potential limitation to this
approach, as with all in vitro work is the lack of heterogeneous cell-cell interaction obtained
in vivo and with primary cells. However, the reduction in use of animals is added benefit.
Furthermore, in addition to being IL-7-dependent, 2E8 cells were sensitive to the same
concentrations of chemicals that were used for primary BM cells in vitro.
In contrast to most studies of As+3 and PAH toxicity involving high dose, short-term
acute, and non-physiological exposures (Carbrey et al., 2009; N’jai et al., 2010; Noreault et
a., 2005), this work focused on very low, environmentally relevant levels of these chemicals
administered through physiological route of exposure. Thus the observations made are
relevant to public health.
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ABSTRACT
It is known that exposure to As+3 via drinking water causes a disruption of the
immune system and significantly compromises the immune response to infection. The
purpose of these studies was to assess the effects of As+3 on bone marrow progenitor
cell colony formation and the humoral immune response to a T-dependent antigen
response (TDAR) in vivo. In a 30 day drinking water study, mice were exposed to 19,
75, or 300 ppb As+3. There was a decrease in bone marrow cell recovery, but not
spleen cell recovery at 300 ppb As+3. In the bone marrow, As+3 altered neither the
expression of CD34+ and CD38+ cells, markers of early hematopoietic stem cells,
nor CD45-/CD105+, markers of mesenchymal stem cells. Spleen cell surface marker
CD45 expression on B cells (CD19+), T cells (CD3+), T helper cells (CD4+) and
cytotoxic T cells (CD8+), natural killer (NK+), and macrophages (Mac 1+) were not
altered by the 30 day in vivo As+3 exposure. Functional assays of CFU-B colony
formation showed significant selective suppression (p < 0.05) by 300 ppb As+3
exposure, whereas CFU-GM formation was not altered. The TDAR of the spleen cells
was significantly suppressed at 75 and 300 ppb As+3. In vitro studies of the bone
marrow revealed a selective suppression of CFU-B by 50 nM As+3 in the absence of
apparent cytotoxicity. Monomethylarsonous acid (MMA+3) demonstrated a dosedependent and selective suppression of CFU-B beginning at 5 nM (p < 0.05). MMA+3
suppressed CFU-GM formation at 500 nM, a concentration that proved to be
nonspecifically cytotoxic. As+5 did not suppress CFU-B and/or CFU-GM in vitro at
concentrations up to 500 nM. Collectively, these results demonstrate that As+3 and
likely its metabolite (MMA+3) target lymphoid progenitor cells in mouse bone
marrow and mature B and T cell activity in the spleen.
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INTRODUCTION
Arsenic occurs ubiquitously in nature as an environmental pollutant found in the air,
soil and water. The pervasive nature of arsenic pollution makes it a major concern globally
despite environmental regulations in some countries. Humans are exposed to some level of
arsenite (As+3) via drinking water, food crops and air, and exposure is associated with many
diseases (Argos et al., 2010). The US EPA set the maximum contaminant level (MCL) for
arsenic in drinking water at 10 ppb. However, in many parts of the US and elsewhere in the
world, people rely on private unregulated wells for their drinking water supply and therefore
are exposed to higher levels of arsenic. Levels exceeding 500 ppb have been found in
domestic well water in some parts of the US (Nielson et al., 2010). Humans are exposed to
two primary forms of inorganic arsenic: trivalent arsenic (As+3) and pentavalent arsenic
(As+5). Both of the forms undergo biotransformation involving reduction and oxidative
methylation in the liver, to form methylated arsenicals such as MMA+5, MMA+3, DMA+5,
and DMA+3 (Drobna et al., 2009; Liu et al., 2006; Thomas et al., 2001). MMA+3 is thought to
be the most toxic arsenic species in vitro (Styblo et al., 2000).
Previous studies have shown that exposure to arsenic via drinking water alters
components of the innate and adaptive immune system in mouse lung and significantly
compromises the immune response to infection (Kozul et al., 2009). Several mechanisms
including interruption of cell signaling, altered expression of transcription factors, oxidative
stress due to formation of reactive oxygen species, increased apoptosis, chromosomal
aberration and inhibition of DNA repair and poly(ADP-ribose) polymerase (PARP) activity
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have been proposed for arsenic toxicity (Argos et al., 2006; Cheng et al., 2004; Cooper et al.,
2013; Flora et al., 2011; Hughes et al., 2011; King et al., 2012; Qin et al., 2012; Sun et al.,
2013). The bone marrow is a vital organ of the immune system in which all immune cells
originate through the process of hematopoiesis. In order to elucidate the role and mechanism
of arsenic in immune suppression, it is necessary to study the effects of environmentally
relevant levels of arsenic on the bone marrow and peripheral lymphoid organs.
Hematopoietic stem cells are able to commit to specific lineages in response to
signal(s) from the microenvironment using the expressed receptor(s) (Carsetti et al., 2000).
Modulation of the bone marrow microenvironment by arsenic may alter stem cell lineage
populations. The pre-B and granulocyte-monocyte colony forming unit (CFU-B and CFUGM) assays are indicators of the bone marrow lymphoid and myeloid responses to
immunotoxicity and may define an aspect of immunity that may be compromised. Studies
show that arsenic exposure impacts the immune system or alters immune responses in
different ways. In humans, experiments show that chronic arsenic exposure causes decrease
in T-cell proliferation and cytokine secretion (Biswas et al., 2008), impairment of
macrophage functions (Banerjee et al., 2009), and increased apoptosis of peripheral blood
mononuclear cells (Rocha-Amador et al., 2011). Given the association of arsenic exposure to
immunosuppression, hematotoxicity, and associated diseases, one would expect that the
immunosuppressive role of arsenic and its metabolites should be evident on the development
of the progenitors as well as peripheral lymphoid organ activity.
Previous studies in our laboratory show that in vitro As+3 exposure produced
immunosuppression at concentrations as low as 500 nM in mouse spleen cells (Li et al.,
2010). The direct effect of As+3 and MMA+3 on bone marrow progenitor cells has not been
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evaluated. To investigate the in vivo effects of As+3, murine bone marrow and spleen cells
were examined following a 30 day oral exposure of mice. CFU-B formation and spleen cell
TDAR activity were suppressed by As+3. The effects of direct exposure of As+3, MMA+3, and
As+5 on in vitro progenitor cell cultures was monitored. Collectively, our results show that
As+3 and MMA+3 selectively suppress the formation of lymphoid progenitors in murine bone
marrow in vitro, demonstrating that lymphoid cell differentiation in the bone marrow and
lymphoid cell activity in the spleen are important targets of arsenic action.
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METHODS
Animals
C57BL/6J male mice were purchased at 8 to 10 weeks of age from Jackson
Laboratory (Bar Harbor, ME) and were acclimated in our AAALAC-approved animal facility
for at least one week before being used in experiments. All animals were handled in
accordance to procedures and protocols approved by the Institutional Animal Use and Care
Committee at the University of New Mexico Health Sciences Center. Following acclimation,
mice (2-3 per cage) were exposed to arsenite (As+3) at different concentrations in parts per
billion (ppb) for 30 days via drinking water. Stock solutions were prepared using sterile
double processed tissue culture water from Sigma-Aldrich. Drinking water bags were
weighed to determine the amount of water consumed by each group of 2-3 mice. Drinking
water contained less than 5 ppb total arsenic. For the in vivo experiments, the concentration
of arsenic in drinking water was periodically checked and validated by the University of
Arizona Laboratory for Emerging Contaminants (ALEC, Tucson AZ). Mouse 2020X Teklad
Global Soy Protein-Free Extruded Rodent Diet, Harlan Laboratories Inc, Madison
Wisconsin, USA, www.harlan.com contained 0.16 mg/kg (160 ppb) of total arsenic, of which
approximately 10-15% may be considered to contain inorganic arsenic species (Kozul et al.,
2008).
Each exposure or treatment group consisted of five mice and bone marrow cells from
each mouse were analyzed in triplicate. In vitro studies were performed using bone marrow
cells pooled together from three untreated C57BL/6J male mice femurs and each treatment
was run in triplicate. All animals exposed to these chemicals were handled with caution,
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using personal protective equipment, and disposed in accordance with the University of New
Mexico’s Risk and Safety Committee and the State of New Mexico guidelines.
Chemicals and Reagents
Sodium arsenite (CAS 774-46-5, Na AsO2) and sodium arsenate dibasic heptahydrate
(CAS 10048-95-0, Na2HAsO4.7H2O) were purchased from Sigma-Aldrich (St. Louis, MO).
Monomethylarsonous acid (MMA+3) >98% purity, was prepared by the Synthesis Core of the
Southwest Environmental Health Sciences Center at the University of Arizona (Tucson, AZ).
MethoCult GF methylcellulose medium (Cat. No. M3534) with recombinant cytokines
(without EPO) for mouse cells was purchased from Stem Cell Technologies (Vancouver, BC,
Canada). Mouse methylcellulose complete media for pre-B cells (Cat. No.HSC009) was
purchased from R&D Systems (Minneapolis, MN).
Isolation of Mouse Bone Marrow Cells
Bone marrow cells were isolated according to the procedure outlined in the Stem Cell
Technologies Technical Manual version 3.1.1(http://www.stemcell.com/). Briefly, each
mouse was sacrificed and 70% isopropyl alcohol was immediately used to wet the ventral fur
to avoid contamination at site of dissection. Both femurs were collected sterilely and placed
and held on ice in Hanks’ Balanced Salt Solution (HBSS) purchased from Lonza
(Walkersville, MD). To extract cells, femurs were placed in petri dish containing cold sterile
RPMI 1640 Medium supplemented with 2% Fetal Bovine Serum (FBS). The ends of the
femurs were trimmed to expose interior marrow shaft. Using a 1 cc syringe with a 25 gauge
needle, approximately 1 ml cold sterile medium was flushed through the femur several times
to release cells into a petri dish. The medium containing cells from both femurs was
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immediately transferred to a 15 ml culture tube and placed on ice until needed. Cells were
washed via centrifugation at 4o C, 400 x g for 10 min and were resuspended in RPMI media
(as above) for culturing or flow cytometry analysis as discussed below. Cell viability was
determined by Acridine Orange/Propidium Iodide (AO/PI) staining and counting using the
Nexcelom Cellometer 2000.
Isolation of Mouse Spleen Cells
Spleen cells were isolated following the procedure described by Lauer et al (Lauer et
al., 2013). Briefly, harvested mouse spleens were weighed and placed in HBSS. Cells from
each spleen were isolated and homogenized by placing the organ between the frosted ends of
two microscopic glass slides and squeezing into a dish containing media. The cell suspension
was centrifuged at 280 x g and 4oC for 10 min. The cell pellets were collected and
resuspended in complete media containing RPMI 1640 (Sigma-Aldrich) w/10 % FBS
(Hyclone Logan, UT), 2 mM L-glutamine (GIBCO by Life Technologies, Grand Island,
NY), 100 µg/ml streptomycin, 100 units/ml penicillin (GIBCO by Life Technologies) and
placed on ice. Cell viability was determined by acridine orange/propidium iodide (AO/PI)
staining and counting using the Nexcelom Cellometer 2000.
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Bone Marrow and Spleen Cell Surface Markers by Flow Cytometry
For bone marrow cell surface marker subset analyses, antibody cocktails for CD34,
CD38, CD45, and CD105 were obtained from BD Biosciences. CD34 and CD38 define early
stages of hematopoietic cell development (Randall et al., 1996) and CD105 defines a
population of CD45- mesenchymal stem cells and stromal cells (Dominici et al., 2006).
Spleen cell surface markers were analyzed using a custom cocktail obtained from BD
Biosciences (San Jose, CA) for CD45, CD3, CD4, CD8, CD19, NK and Mac1 for spleen
cells as previously described, (Lauer et al., 2013). The control cocktail for the BM included
isotype controls and CD45-PerCP (IgG2a-FITC; IgG2a-PE, CD45-PerCP;IgG2a-Alexa647),
and the test cocktail included CD34-FITC; CD38-PE; CD45-PerCP; CD105-Alexa647.
Briefly, 100 µl of media containing 1 X106 bone marrow cells were incubated with 20 µl of
cocktail for 30 min at RT in the dark. Red blood cells were lysed by incubating with 2 ml of
ammonium chloride lysing solution (0.15M ammonium chloride, Sigma A-4514; 10mM
sodium bicarbonate, Sigma S-5716; 1mM disodium EDTA, Sigma-E7889; pH 7.4) for 10
min. The cells were centrifuged at 275 x g for 10 min, the supernatant was aspirated and the
cells washed with 2 ml Dulbecco’s phosphate buffered saline (DPBS) w/o Ca+2 and Mg+2
containing 1% FBS and 0.9% sodium azide (PBS/FBS). The washed cells were resuspended
in 0.5 ml PBS/FBS and 20,000 cells were analyzed using the Accuri C6 Flow Cytometer
(Becton Dickinson, San Jose, CA). The percent positive cell population was determined by
gating on CD45+ cells and subtracting out background determined from the isotype controls
for each sample. Spleen cell surface markers were analyzed as previously described (Lauer et
al., 2013), using custom cocktail from BD Biosciences containing antibody reagents for
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CD3(FITC)/CD8a(PE)/ CD45(PerCP)/CD4(APC) or CD3+CD19(FITC)/PanNK(PE)/
CD45(PerCP)/Mac-1(APC).
T-Dependent Antibody Assay
For the T-dependent antibody response (TDAR) assay, mice were immunized with
0.2 ml of 10% sheep red blood cells (Colorado Serum, Denver CO) in saline 4 days prior to
euthanization. Following spleen harvesting, cells were washed and suspended at 4x106
cell/ml in supplemented media. A mixture of 100 µl cells (4x105), 50 µl washed 1% sheep
red bloods cells and 400 µl of 0.8% low-melting point SeaPlaque agarose (Lonza, Rockland,
ME) solution (in RPMI held at 42°C) were combined and poured onto an agarose coated
slide. Agarose was allowed to set-up before incubating face down on custom slide trays in a
humidified plastic box at 37°C for 1.5 hour. Guinea pig complement (Colorado Serum,
Denver, Colorado) was diluted 1:20 in Dulbecco’s Phosphate Buffered Saline containing
Ca2+ and Mg2+ (Sigma) and warmed to room temperature. Slides were flooded with diluted
complement following the 1.5 hour incubation and then incubated, as described above for an
additional 2 hrs. Slides were removed from the incubator and stored in a cold 0.85% sodium
chloride solution. SRBC lysis was quantified by counting plaques in the SRBC/agar lawn
using a dissecting microscope. Results are expressed as plaque forming cells (PFC) per
culture of 4x105 cells.
CFU-B Assay
This assay was performed as described in Stem Cell Technologies Technical Manual
version 3.1.1 (http://www.stemcell.com/) for Mouse Colony-Forming Cell (CFC) Assays
using MethoCult. Briefly, isolated bone marrow cells from each mouse (for in vivo studies)
35

or pooled from three mice (for in vitro studies) were suspended in RPMI 1640 Medium
supplemented with 2% heat inactivated Hyclone Fetal Bovine Serum (Fisher Scientific,
Pittsburgh, PA) at 1x106 cells/ml. 400 µl (4 x105 cells) of the cell suspension was transferred
to a 16 ml (17 x 100 mm) sterile culture tube which contained 4 ml Mouse Methylcellulose
Complete Media for Pre-B Cells (R&D Systems, Minneapolis, MN).The tube was thoroughly
mixed by vortexing and allowed to sit for 20 min to release air bubbles. 1 ml of the
methylcellulose-cell mixture was dispensed into a 35 mm culture dish (Stem Cell
Technologies) using a 3 cc syringe with a 16G x 11/2’’ Monoject Aluminum Hub, blunt
canula needle from Covidien (Mansfield, MA).Samples were run in triplicate. The mixture
was evenly dispersed in the dish by rocking the dish. One sterile water dish and two sample
dishes were placed in a 100 mm culture dish and incubated at 37oC, 5% CO2, in a humidified
incubator for 10 days. CFU-B colonies were counted and recorded for statistical analysis.
CFU-GM Assay
The same initial methods as in the CFU-B assay described above were used for the
CFU-GM assay except that the isolated bone marrow cells were suspended in Iscove’s
Modified Dulbecco’s Medium (Sigma-Aldrich) supplemented with 2% heat inactivated
Hyclone Fetal Bovine Serum at 2x105 cells/ml. 400 µl (8x104 cells) of the cell suspension
was transferred to a 16ml (17x100 mm) sterile culture tube which contained 4 ml MethoCult
GF Methylcellulose Medium (Stem Cell Technologies). As described above for CFU-B, the
mixture was evenly dispersed in the dish by rocking the dish. Sample dishes (35 mm) were
placed in a 100 mm culture dish and put in the humidified incubator at 37oC and 5% CO2 for
14 days. CFU-GM colonies were counted and recorded for statistical analysis.
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Annexin V Staining
Bone marrow cells from femurs of three male C57BL6/J mice were pooled together
and incubated in RPMI media supplemented with 2% FBS, 2 mM L-glutamine, 100 units/ml
penicillin and 100 units/ml streptomycin with treatment for 18 hrs. Following incubation the
cells were washed in PBS by centrifuging at 300 x g. Cells were resuspended and stained in
solutions and reagents provided in the FITC Annexin V Apoptosis Detection kit (BD
Biosciences) according to manufacturer’s procedure. Stained cells were analyzed using the
Accuri C6 Flow Cytometer. Cells were selected using FSC and SSC and then analyzed based
on percentage of stained cells.
Data Analysis and Statistics
Data were analyzed using the Sigma Stat version 3.5 and Sigma Plot 12.0 software,
one-way analysis of variance (ANOVA) and Dunnett’s t-test to determine differences
between control and treatment groups. For in vivo studies, treatment groups consisted of five
animals and each animal was analyzed in triplicate. Bone marrow cell recovery was
expressed as the mean number of recovered bone marrow cells obtained from a pool of both
femurs. In the in vitro experiments, a treatment group consisted of three replicates of one
chemical treatment of pooled bone marrow cells or control. We calculated the number of
CFU-B and CFU-GM formed per 106 cells plated at the beginning of the culture periods.
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RESULTS
C57BL/6J male mice (5 per group) were given 0, 19, 75, or 300 ppb As+3 via drinking
water for 30 days. As shown in Table 1, at the end of the 30 day period, there were no
significant differences in body weights or spleen weights between groups and arsenic
contained in the drinking water did not affect the amount of water consumed by the mice.
There was an apparent trend towards a dose-dependent reduction in bone marrow cell
recovery, which was significant at the 300 ppb As+3 exposure level (p<0.05). Spleen cell
recovery was not affected by As+3 at any exposure level.
Flow cytometry analysis of the bone marrow cell surface markers demonstrated that
the percentage of early stem cells CD45+/CD34+ and CD45+/CD38+ (which define early
hematolymphoid cells, (Randall et al., 1996)) was not changed by As+3 consumption (Figure
2.1, top). Also, there was no significant difference in CD45-/CD105+ (markers of
mesenchymal stem cells, (Dominici et al., 2006)) expression between control and treatment
groups (Figure 2.1, bottom).
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Figure 2.1. Bone marrow (BM) cell surface marker expression analyzed by flow cytometry.
Percent CD34+ and CD38+ mice BM cells co-expressing CD45 [Top] and percent BM cells
expressing CD105 [Bottom] in CD45+ and CD45- cells after 30 day consumption of As+3 in
drinking water. Results are Means + SD.
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In the spleen, there were no differences in cell surface marker expression for
mature B (CD45+/CD19+), T (CD45+/CD3+), helper T (CD45+/CD4+), cytotoxic T
(CD45+/CD8+), natural killer (CD45+/NK+), and macrophage (CD45+/Mac-1+)
populations between control and treatment groups (Figure 2.2, Top and bottom).
Since the purpose of these studies was to assess the effects of As+3 on lymphoid cell
differentiation and function, we examined the colony forming unit (CFU) activity of pre-B
cells and granulocyte-monocyte (GM) CFUs as well as peripheral lymphoid (spleen) cell
function. As+3 was found to decrease the numbers of CFU-B measured in the femurs of the
300 ppb group (Figure 2.3, top), but it did not affect the number of CFU-GM detected
(Figure 2.3, bottom). These results show a selective loss in lymphoid CFU activity, but not
myeloid activity without altering the early progenitors (as measured by CD34/CD38)
detected by flow cytometry.

41

Figure 2.2. Spleen cell surface marker expression analyzed by flow cytometry. Percent
CD19+, CD3+, NK and Mac 1 cells co-expressing CD45 [Top] and percent CD4+ or
CD8+ cells co-expressing CD45 [Bottom] after 30 day consumption of As+3 in drinking
water. Results are Means + SD
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Figure 2.3. In vivo BM exposure to As+3 showing number of colonies per pair of mice
femurs. Number of CFU-B colonies in a pair of mice femurs, 10 days post plating in
mouse methylcellulose media for pre-B [Top]. Number of CFU-GM colonies in a pair of
mice femurs 14 days post plating in Methocult media for GM selection [Bottom] after 30
day consumption of As+3 via drinking water. *Significantly different compared to control
(p<0.05). Results are Means + SD.
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The T-dependent antibody response to sheep red blood cells was suppressed at both
the 75 and 300 ppb exposure levels in the spleen (Figure 2.4) suggesting that immature and
mature lymphoid lineages are sensitive to the effects of As+3.
To determine whether As+3 has direct effects on bone marrow progenitor cells, we
performed in vitro studies with known concentrations of As+3 over a wide concentration
range. These studies also allowed us to examine the effects of MMA+3 on lymphoid and
myeloid progenitor cultures, which is important because MMA+3 is a key and oftentimes
more toxic metabolite of arsenite. In agreement with our in vivo studies, we found that pre-B
cells were more sensitive than CFU-GM progenitors to in vitro exposure to As+3 (Figure 2.5).
As+3 was found to suppress CFU-B formation at concentrations as low as 50nM, whereas,
this concentration and 500 nM As+3 did not affect CFU-GM formation.
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Figure 2.4. Suppression of T-dependent antibody response to sheep red blood cells post
30 day in vivo exposure of mice to As+3 via drinking water. After As+3 exposure, mice
were immunized with SRBCs and examined for in vitro antibody production 4 days later.
Results are Means + SD.
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Figure 2.5. Number of colonies per million cells exposed to As+3 in vitro. Number of CFUB colonies per million cells 10 days post plating in mouse methylcellulose media
(containing As+3) for pre-B cells [Top]. Number of CFU-GM colonies per million cells 14
days post plating in mouse methylcellulose media (containing As+3) for GM cells [Bottom].
* Significantly different compared to control (p<0.05). Results are Means + SD.
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Exposure of murine bone marrow cells to MMA+3 was also found to selectively
suppress pre-B colony formation. There was a concentration-dependent suppression of CFUGM by MMA+3 (Figure 2.6, bottom). At concentrations as low as 5 nM MMA+3, CFU-B
formation was significantly suppressed (Figure 2.6, top), suggesting that MMA+3 may be
approximately ten times more potent than As+3 in suppressing CFU-B formation. MMA+3
suppression of CFU-GM formation was significant at a concentration of 500 nM (Figure 2.6,
bottom). The in vitro exposure to 500 nM MMA+3 proved to be nonspecifically cytotoxic to
bone marrow cultures, as revealed by cell viability and Annexin V studies performed at 18
hrs after exposure (Table 2.2). Annexin V positive cells were found with both propidium
iodide positive and negative cell populations, suggesting a mixed mode of cell death.
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Figure 2.6. Number of colonies per million cells exposed to MMA+3 in vitro. Number of
CFU-B colonies per million cells 10 days post plating in mouse methylcellulose media
(containing MMA+3) for pre-B cells [Top]. Number of CFU-GM colonies per million cells 14
days post plating in mouse methylcellulose media (containing MMA+3) for GM cells
[Bottom]. *Significantly different compared to control (p<0.05). Results are Means + SD.

48

Table 2.2: In vitro (18 hrs.) As+3, As+5 or MMA+3 Exposure and Effects on Mouse
Bone marrow Cell Viability1

Treatments

% Viability
(Cellometer)

% Annexin V
negative/PI
negative cells

% Annexin V
positive/PI
negative cells

% Annexin V
negative/PI
positive cells

Control

63.2 + 1.4

78.1 + 2.7

16.1 + 2.5

5.7 + 0.2

5 nM As+3

63.3 + 0.6

77.8 + 2.2

16.3 + 2.1

5.8 + 0.8

50 nM As+3

58.4 + 3.5

76.2 + 1.3

17.8 + 0.6

5.8 + 0.5

500 nM As+3

59.8 + 1.7

75.6 + 2.0

18.4 + 0.4

6.0 + 1.7

5 nM As+5

59.3 + 0.1

77.8 + 1.8

16.7 + 0.3

5.4 + 1.4

50 nM As+5

58.8+3.7

75.9 + 1.4

17.1 + 1.5

6.7 + 0.4

500 nM As+5

62.7+ 2.2

74.3 + 0.8

19.2 + 1.2

6.4 + 0.5

5 nM MMA+3

59.3 + 3.5

76.5 + 1.9

17.6 + 2.0

5.8 + 0.2

50 nM MMA+3

59.9 + 6.8

78.2 + 0.5

16.6 + 0.5

5.0 + 0.6

500 nM MMA+3

39.5 + 10.0*

52.0 + 2.5*

21.6 + 3.4*

26.4 + 2.2*

1

Bone marrow cells from three mice femurs were pooled and exposed to each treatment in
triplicate. Results are Means + SD with statistical significance at *p<0.05
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The in vitro exposure to 500 nM MMA+3 proved to be nonspecifically cytotoxic to
bone marrow cultures, as revealed by cell viability and Annexin V studies performed at 18
Finally, since many drinking water sources are contaminated with inorganic pentavalent
arsenate (As+5), we examined the effects of As+5 on mouse bone marrow progenitor cell
activity in vitro. As+5 did not inhibit CFU-B or CFU-GM colony formation at concentrations
as high as 500 nM (Figure 2.7). These results demonstrate that As+5 is far less toxic to the
bone marrow than the trivalent arsenicals in mice.
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Figure 2.7. Number of colonies per million cells exposed to As+5 in vitro. Number of CFU-B
colonies per million cells 10 days post plating in mouse methylcellulose media (containing
As+5) for pre-B cells [Top]. Number of CFU-GM colonies per million cells 14 days post
plating in mouse methylcellulose media (containing As+5) for GM cells [Bottom]. No
significant differences between treatments and control (p<0.05) were found. Results are
Means + SD.
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DISCUSSION

Arsenic is considered to be one of the most important global environmental risk
factors for human diseases (Argos et al., 2010). There is increasing evidence that arsenic
alters immune activity function in human populations. Many of the current findings rely on
the use of peripheral blood and biomarkers to infer the cells and organs that are affected by
arsenic (Andrew et al., 2006; Argos et al., 2006; Biswas et al., 2008; Soto-Pena et al., 2006).
In addition, there have been in vitro studies with arsenite (As+3) at micro molar
concentrations in human leukocytes that demonstrate altered immune effects possibly by
affecting T cells and macrophage/dendritic cells (Macoch et al., 2013; Morzadec et al.,
2012a, 2012b). Also, it has been observed that micro molar concentrations of As+3 induce
necrosis of human CD34+ bone marrow cells (Vernhet et al., 2008). These studies are
interesting because arsenic trioxide is used clinically for the treatment of certain leukemia
and myelodysplastic syndromes (Lengfelder et al., 2012).
Previous studies using environmentally relevant levels of exposure have shown that
low levels of As+3 given in drinking water to mature mice increased their susceptibility to
influenza virus (Kozul et al., 2009). Our present studies followed a similar design (30 day
exposure, at concentrations up to 300 ppb As+3). We found that As+3 produced a significant
suppression of pre-B colony formation in the bone marrow. While the effects of As+3 on bone
marrow could contribute to the immune suppression associated with influenza and other
infections, there are numerous other immunologic abnormalities that could result from effects
on the bone marrow. The hematopoietic system continually replenishes itself throughout life
and is one of the most sensitive targets for cytotoxic and anti-proliferative agents, often being
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the dose limiting organ/tissue for radiation and chemotherapy. The immune system that
develops during embryogenesis has been found to be extremely sensitive to environmental
chemical effects (Irons, 1985). There is evidence that the development of lymphoid tissues is
altered by environmental arsenic exposure, as thymic defects have been detected in
developmentally-exposed human populations (Ahmed et al., 2012).
To better understand the mechanisms of action associated with arsenic
immunotoxicity, several labs have established animal models. Our own studies have shown
that exposure of mice to arsenic trioxide via inhalation causes suppression of the Tdependent antibody response (Burchiel et al., 2009). The effect of As+3 may involve a
complex action on the activation and differentiation of both lymphoid (B and T) and myeloid
(macrophages and dendritic) cells. Therefore, in the present studies, we were interested in
characterizing the effects of arsenic on lymphoid and myeloid cell development in the bone
marrow following in vivo 30 day drinking water and in vitro exposures. Trivalent arsenite is
known to be one of the toxic species of arsenic that can form in the body following in vivo
drinking water exposure to arsenic. The toxicity of arsenic in vivo would depend on the type,
quantity and stability of the specific arsenic metabolites formed through biotransformation
(Styblo et al., 2000). A key organic metabolite of arsenite formed through metabolism by the
enzyme arsenite 3-methyltransferase (AS3MT) is MMA+3 (Aposhian et al., 2000). To
investigate the relative contribution of each arsenic species that could lead to bone marrow
suppression, we directly exposed bone marrow cells to different arsenic species, including
As+3, MMA+3 and As+5. As+3 significantly and selectively inhibited the lymphoid (CFU-B)
progenitor formation at 50 nM, but had no effect on the myeloid progenitors (CFU-GM),
even at 500 nM examined in vitro. The selective effects of As+3 on lymphoid progenitors are
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therefore consistent between our in vivo and in vitro studies. The lymphoid progenitor CFUB colony formation was significantly suppressed by 5 nM MMA+3 in vitro, whereas the
myeloid progenitor cells (CFU-GM), were suppressed at 500 nM MMA+3, indicating a
hundred fold difference in sensitivity. The lack of significant changes in viability, Annexin V
staining and PI staining 18 hrs following in vitro exposure to As+3 (up to 500 nM), MMA+3
(up to 50nM), and As+5 (up to 500 nM) may be an indication that cell death is not responsible
for the BM suppression observed with the 300 ppb in vivo As+3 exposure. The 500 nM
MMA+3 dose that caused the reduction in cell viability and increased Annexin V and PI
staining also completely inhibited CFU-B colony formation, but only suppressed CFU-GM
formation by 50%. The selectivity is thus clear but raises question in regard to mechanism.
In vitro exposure of murine bone marrow cells to As+5 showed that this agent did not
significantly inhibit CFU-B or CFU-GM colony formation at concentrations up to 500 nM.
MMA+3 has been found in the blood and urine of human subjects who were exposed to high
levels of inorganic arsenite via drinking water (Aposhian et al., 2000; Gamble et al., 2007). It
is produced in the liver and kidneys through the metabolism of arsenate or arsenite by the
action of the enzymes arsenate/arsenite reductases, AS3MT, and MMA+5 reductase. AS3MT
is a polymorphic enzyme in the human that has been shown to correlate with the toxicity of
arsenic in drinking water (Engstrom et al., 2013; Fujihara et al., 2010; Meze et al., 2007).
AS3MT has been detected in rodent tissues, primarily in liver and kidney (Healy et al., 1998)
and is also expressed in human peripheral blood (Engstrom et al., 2011). Therefore, our
studies demonstrate that it is important to understand the relative actions of important
arsenite metabolites formed in vivo, such as MMA+3, and the exposure levels received by the
bone marrow and other lymphoid organs.
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In summary, this study has demonstrated for the first time the sensitivity
subpopulations of the bone marrow to inorganic and organic arsenicals. The fact that
lymphoid progenitors are more sensitive to suppression than myeloid progenitors suggests
that there may be novel targeting mechanisms associated with cell activation and cell
differentiation that are affected by As+3 and MMA+3 in murine bone marrow cells. Future
studies will address various mechanisms that may be associated with arsenite inhibition of
CFU-B formation and will also examine the effects of arsenite and MMA+3 on early T cell
development.
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ABSTRACT

Arsenite and Dibenzo[def,p]chrysene (DBC), a polycyclic aromatic hyrdrocarbon
(PAH), are found in nature as environmental contaminants. Both are known to individually
suppress the immune system of humans and mice. In order to determine their potential
interactive and combined immunosuppressive effects, we examined murine bone marrow
(BM) immune progenitor cells response following combined oral exposures at very low
levels of exposure to As+3 and DBC . Oral 5 day exposure to DBC at 1 mg/kg (cumulative
dose) was found to suppress mouse BM lymphoid progenitor cells, but not the myeloid
progenitors. Previously established no-effect doses of As+3 in drinking water (19 and 75 ppb
for 30 days) produced more lymphoid suppression in the bone marrow when mice were
concomitantly fed a low dose of DBC during the last 5-days. The lower dose (19 ppb) As+3
had more suppressive effect with DBC than the higher dose (75 ppb).Thus the interactive
toxicity of As+3 and DBC in vivo could be As+3-dose dependent. In vitro, the suppressive
interaction of As+3 and DBC was also evident at low concentrations (0.5 nM), but not at
higher concentrations (5 nM) of As+3. These studies show potentially important interactions
between As+3 and DBC on mouse BM at extremely low levels of exposure in vivo and in
vitro.

58

INTRODUCTION

Arsenic and polycyclic aromatic hydrocarbons (PAHs) are environmental toxicants
that are individually known to produce immunotoxicity in humans and mice (Argos et al.,
2010; Burchiel et al., 2014; Kozul et al., 2009; Li et al., 2010; N’jai et al., 2010) . Our
previous studies showed that As+3 given orally at low levels selectively suppressed bone
marrow (BM) lymphoid progenitor cells response in vivo and in vitro, and spleen Tdependent antibody responses (TDAR) in vitro (Ezeh et al., 2014). Immunosuppression is
one of the major adverse manifestations of As+3 and PAH exposures. Dibenzo[def,p]chrysene
(DBC), like the highly toxic 7,12-diemthylbenz(a)anthracene (DMBA), is known to suppress
T-dependent antibody responses (TDAR) of murine spleen cells following in vivo and in
vitro exposures (Gao et al., 2005; Gao et al., 2007; Gao et al., 2008; Lauer et al., 2013) and,
in combination with As+3, these PAHs were found to produce synergistic immunosuppression
of the TDAR in vitro (Li et al., 2010).
Our studies were motivated by the knowledge that PAHs produce
immunosuppression in lymphoid organs, such as spleen and BM, through the formation of
reactive metabolites that form DNA adducts with induction of p53 (Gao et al., 2005; Gao et
al., 2007, 2008; Galvin et al., 2003, 2006). Since PAH-adducts can be repaired by both DNA
Base Excision Repair (BER) and Nucleotide Excision Repair (NER) pathways that are
sensitive to inhibition by As+3 (Qin et al., 2012; Zhou et al., 2011), we postulated that low
concentrations of PAHs that are not cytotoxic to BM may produce increased immunotoxicity
in the presence of As+3.
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We sought to investigate the possible influence of co-exposure to both pollutants and
their possible interactions in the BM in mice at very low levels through physiologically
relevant routes of exposure. Concentrations of 19 and 75 ppb As+3 in 30 day drinking water
were previously established to be non-toxic to the BM (Ezeh et al., 2014), and 0.1 and 1
mg/kg cumulative doses of DBC in pill forms (Lauer et al, 2013) were chosen based on
previous dose-range studies.
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METHODS
Animals and Treatment Exposures
C57BL/6J mice were purchased from Jackson Laboratory, Bar Harbor, Maine, USA,
at 8 -10 weeks old and housed in our AAALAC-approved facility, for use in this study at 1216 weeks. These animals were handled according to procedures and protocols that have been
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of
New Mexico Health Sciences Center. All applicable international, national, and/or
institutional guidelines for the care and use of animals were followed. About 2-3 animals
were housed per cage and exposed to different concentrations of arsenite (As+3) in parts per
billion (ppb) for 30 days via drinking water and/or exposed to Dibenzo[def, p]chrysene
(DBC) by voluntary ingestion of a pill containing the chemical. Double processed tissue
culture water (Sigma Aldrich), was used to prepare arsenite stock solutions. The cookie pill
containing the DBC was prepared using Transgenic Dough Diet, DMSO, bromophenol blue
and DBC according to the procedure previously described (Lauer et al., 2013).
Water samples were collected periodically and sent to University of Arizona
Laboratory for Emerging Contaminants (ALEC, Tucson AZ) to determine the As+3
concentrations in the control (no As+3) drinking water and to confirm As+3 levels in prepared
solutions used for these studies. The concentration of As+3 in the control drinking water and
that used to make solutions was found to be less than 5 ppb. For the water consumption of
the mice in each cage, the water bags containing water were weighed prior to placement in
the cage and again after water consumption by the mice. Mice were fed a Mouse 2020X
Teklad Global Soy Protein-Free Extruded Rodent Diet purchased from Harlan Laboratories
Inc, Madison Wisconsin, USA, www.harlan.com . The total arsenic content of this diet was
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found to be 0.16 mg/kg (160 ppb), with approximately 10–15% estimated to be inorganic
arsenic, As+3 and As+5, as discussed previously (Kozul et al., 2009).
For in vivo studies, 45 male C57BL/6J mice were exposed to As+3 via drinking water
for 30 days and/or exposed to DBC via pill ingestion. The mice were treated in groups of
four or five for each treatment and bone marrow cells (BM) from each exposed mouse was
isolated and analyzed in triplicate. For in vitro studies, bone marrow cells isolated from both
femurs of three untreated C57BL/6J mice were pooled together, exposed to each treatment
and analyzed in triplicate. All animals were handled and disposed of in accordance with the
University of New Mexico's Department of Safety and Risk Services protocol.
Chemicals and Reagents
Sodium arsenite (CAS 774-46-5, NaAsO2) was purchased from Sigma-Aldrich (St.
Louis, MO). The PAHs were purchased or obtained at greater than 95% purity from the
following sources: dibenzo[def, p]chrysene (DBC, Accustandard), DBC-11,12 dihydrodiol
was provided by Dr. David Williams at Oregon State University. MethoCult GF
Methylcellulose Medium (Cat. No. M3534) with recombinant cytokines (without EPO) for
mouse cells was purchased from Stem Cell Technologies (Vancouver, BC, Canada). Mouse
Methylcellulose Complete Medium for pre-B cells (Cat. No. HSC009) was purchased from
R&D Systems (Minneapolis, MN).
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Arsenic and PAH handling
Arsenic, DBC and DBC-diol and all animals exposed to these chemicals were handled and
disposed according to the University of New Mexico's Department of Safety and Risk
Services protocol.
Isolation of Mouse Bone Marrow Cells
Bone marrow cells were isolated according to the procedure outlined in the Stem Cell
Technologies Technical Manual version 3.1.1(http://www.stemcell.com/) and as described in
previous work (Ezeh et al., 2014). Briefly, each mouse was euthanized and the femurs were
sterilely harvested, then placed and held on ice in Hanks' Balanced Salt Solution (HBSS)
from Lonza Walkersville, MD, and transported to the laboratory. Bone marrow cells were
extracted from the femurs using a 25 gauge needle with a 1 cc syringe, filled with
approximately 1 ml cold sterile medium which was used to flush through the femur several
times to release cells into a cell culture dish containing RPMI medium that was supplemented
with FBS. The cells solution was immediately transferred to a 15 ml culture tube and placed
on ice until needed. Cells were washed by centrifugation at 4°C, 300 X g for 10 min and were
resuspended in RPMI Medium for culturing. Cell recovery and viability was determined by
manual counting or automated counting using the Nexcelom Cellometer 2000.
CFU-B Assay
The procedure for Mouse Colony-Forming Cell (CFC) assays described in the Stem
Cell Technologies Technical manual version 3.1.1(http://www.stemcell.com/) was used to
determine the pre-B colony forming units (CFU) counts per pair of mice femurs and per
million bone marrow cells. Briefly, bone BM cells marrow cells isolated from femurs of each
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treated or untreated mouse (for in vivo studies) or pooled from femurs of three untreated mice
(for in vitro studies), were suspended in RPMI 1640 Medium supplemented with 2% heat
inactivated Hyclone Fetal Bovine Serum (Fisher Scientific, Pittsburgh, PA) at 1×106cells/ml.
400 μl (4×105 cells) of the cell suspension was transferred to a 16 ml (17×100 mm) sterile
culture tube containing 4 ml Mouse Methylcellulose Complete Media for pre-B Cells. The
tube was vortexed and left to sit for 20 min to release air bubbles. 1 ml of the
methylcellulose-cell suspension was placed in a 35 mm culture dish (Stem Cell
Technologies) using a 3 cc syringe with a 16G×11/2″ Monoject Aluminum Hub, blunt
cannula needle (Covidien, Mansfield, MA). Samples were ran in triplicate. The mixture was
evenly dispersed in the dish by rocking the dish. One sterile water dish and two sample
dishes were placed into a 100 mm culture dish and incubated at 37°C, 5% CO2, in a
humidified incubator for 10 days. CFU-B colonies were counted and recorded for statistical
analysis.
CFU-GM Assay
This assay was performed using the same procedure as in the CFU-B assay described
above except that the isolated bone marrow cells were suspended in Iscove's Modified
Dulbecco's Medium (Sigma-Aldrich) supplemented with 2% heat inactivated Hyclone Fetal
Bovine Serum at 2×105 cells/ml, and 400 μl (8×104 cells) of the cell suspension was
transferred to a 16 ml (17×100 mm) sterile culture tube containing 4 ml MethoCult GF
Methylcellulose Medium (Stem Cell Technologies). Like in the CFU-B assay described
above, the mixture was dispersed evenly in the dish and sample dishes (35 mm) were placed
in a 100 mm culture dish and put in the humidified incubator at 37°C and 5% CO2 for 14
days. CFU-GM colonies were counted and recorded for statistical analysis.
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Data Analysis and Statistics
Sigma Stat version 3.5 and Sigma Plot 12.0 software were used for data analysis.
One-way analysis of variance (ANOVA) and Dunnett's t-test were applied to determine
differences between control and treatment groups. In the in vivo studies, treatment groups
consisted of four or five animals and each animal was analyzed in triplicate. Bone marrow
cell recovery was expressed as the mean number of recovered bone marrow cells obtained
from both femurs, Results were reported as CFU-B and CFU-GM per million cells and also
per pair of femurs. For the in vitro experiments, a treatment group consisted of three
replicates of one chemical treatment of pooled bone marrow cells or control. CFU-B and
CFU-GM colony counts were reported as per million cells.
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Table 3.1 Effect of cumulative 5 day in vivo exposure to DBC on mice BM cell recovery and
viabilitya

DBC (mg/kg)

BM Cell Count (x 107)

Viability (%)

0

5.9 + 1.6

98.8 + 2.4

0.01

6.8 + 1.9

100 + 0.0

0.1

7.4 + 1.7

99.3 + 1.5

1

4.8 + 0.9

100 + 0.0

10

5.8 + 3.0

93.0 + 8.6

a

Results shown are the Means + SD
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Figure 3.1. Pre-B colony formation in mice post 5 day in vivo cumulative exposure to
DBC. Number of CFU-B colonies per million BM cells [a] or per set of femurs [b] in mice
following 5 day in vivo exposure to DBC via oral pill ingestion, 10 days post plating in
mouse methylcellulose media for pre-B cell selection. *Significantly different compared to
control (p< 0.05). Data shown are Means + SD.
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RESULTS

C57BL/6J male mice, consisting of 4 mice per treatment dose, were exposed to 0,
0.01, 0.1, 1 or 10 mg/kg cumulative dose of DBC via voluntary ingestion of DBC pills daily
for 5 days. As shown in Table 3.1, at these exposure concentrations, there was no effect on
the recovery of viable cells from the BM. A dose-dependent decrease in CFU-B formation
was detected when expressed on a per million cell basis (Fig. 3.1a) and on a per pooled
femur basis (Fig. 3.1b). Greater than 90% inhibition of CFU-B colony formation was
observed at the 10 mg/kg total cumulative dose of DBC given over 5 days.
Based on our previous work, we were interested in determining whether concomitant
exposure of mice to low or no-effect doses of As+3 with low levels of DBC could produce
significantly more suppression of the BM. In an in vivo experiment using 5 mice per dose
group, mice were exposed to 0, 19, or 75 ppb As+3 in drinking water for 30 days in the
absence or presence of DBC at 0.1 or 1 mg/kg given during the last 5 days of As+3 exposure.
As expected, results showed that neither As+3 nor DBC suppressed CFU-B levels on their
own when expressed on a per million cell basis (Fig. 3.2a), but the combined exposures to 19
ppb As+3 and 1 mg/kg DBC did show significant suppression which was more than that seen
in the 75 ppb As+3 and DBC individual exposures . DBC produced a small decrease in BM
cell recovery at the 1 mg/kg exposure (Table 3.2) which resulted in a significant effect on
CFU-B formation when expressed on an individual mouse pooled femur basis (Fig. 3.2b). An
additional finding was that these combinations of As+3 and DBC did not suppress the
formation of CFU-GM colonies (Fig. 3.2c, 3.2d).
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Table 3.2 In vivo low dose As+3 + DBC has no effect on the cell recovery and viability of mice
BM cellsa

Treatment

Cell count (x 107)

Viability (%)

Control

3.2 + 1.2

93.1 + 3.6

19 ppb As+3

3.0 + 0.2

92.4 + 1.6

75 ppb As+3

3.0 + 0.8

93.1 + 2.8

0.1 mg/kg DBC

3.0 + 0.7

94.0 + 2.2

1 mg/kg DBC

2.3 + 0.5

93.0 + 1.1

19 ppb As+3 + 0.1 mg/kg DBC 3.3 + 0.4

92.7 + 2.8

19 ppb As+3 + 1 mg/kg DBC

3.2 + 0.7

94.4 + 1.4

75 ppb As+3 + 0.1 mg/kg DBC 3.4 + 0.4

92.8 + 2.2

75 ppb As+3 + 1 mg/kg DBC

93.1 + 2.5

a

3.2 + 0.7

Results shown are the Means + SD
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Figure 3.2. CFU-B and CFU-GM colony formation in mice post in vivo exposure to low level
of As+3 + DBC. Number of CFU-B colonies per million BM cells [a] or per set of femurs [b];
Number of CFU-GM colonies per million BM cells [c] or per set of femurs [d] in mice
following 30 day in vivo exposure to As+3 via drinking water + 5 day DBC exposure via oral
ingestion. BM cells were plated in mouse methylcellulose media for pre-B cell selection for
10 days or in methocult media for GM selection for 14 days. *Significantly different
compared to control (p<0.05). #Significantly different compared to effect of DBC or As+3
given as individual treatments at the selected dose. Data shown are Means + SD.
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These findings are consistent with our previous studies showing the selective
suppression of CFU-B in mouse BM following 30 day low level As+3 exposures (Ezeh et al.,
2014).
To further investigate the possibility of As+3 interaction with DBC in the BM, mice
BM cells were exposed to various concentrations of As+3, DBC, and DBC-diol (a DBC
metabolite known to be the immediate precurosor of DBC-diol epoxide, which is thought to
be important in DBC adduct formation in DNA) in vitro. Based on preliminary studies to
determine no-effect doses of agents, we used 0.5 and 5 nM concentrations of As+3 and 0.1
and 1 nM concentrations of DBC (Fig. 3.3a). We found that these levels of As+3 and DBC
given alone did not suppress CFU-B formation in vitro. However, low concentratiions of
As+3 (0.5 nM) produced CFU-B suppression when combined with low level (0.1 nM) of
DBC or DBC-diol (Fig. 3.3a). The colony count in the As+3/DBC-diol combination was
significantly different compared to both control and the individual parent compounds at the
same doses, suggesting interaction. Increased As+3 concentration (5 nM) also produced
suppression of CFU-B in the presence of 0.1 nM and 1 nM DBC, but not in the presence of
DBC-diol. There were no interactions between As+3 and DBC at the higher concentrations of
exposure.
Since we previously found that MMA+3 (an As+3 metabolite) may be responsible for
the toxicity of As+3 on BM in vivo (Ezeh et al., 2014), we investigated possible interaction of
MMA+3 with DBC or DBC-diol in in vitro cultures, using one concentration (5 nM) that
was previously established to be minimally toxic to the BM and another ten times lower
concentration (0.5 nM). Both concentrations of MMA+3 suppressed CFU-B formation in
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mouse BM (Fig. 3.3b). However, we observed MMA+3/DBC interacton at the higher
concentrations of both chemicals but not at the lower concentrations nor with DBC-diol.
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Figure 3.3. In vitro exposure of mice BM cells to As+3 + DBC or DBC-diol.
Number of CFU-B colonies per million cells in untreated mice BM cells post 10 day plating in
pre-B mouse methylcellulose media containing As+3 + DBC or DBC-diol [a], or containing
MMA+3 + DBC or DBC-diol [b]. #Significantly different compared to effect of DBC or As+3
given as individual treatments at the selected dose. *Significantly different compared to
control (p<0.05). Data shown are Means + SD.
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DISCUSSION

The present studies demonstrate for the first time that As+3 interacts with DBC when
given orally at low doses in vivo and selectively suppresses pre-B formation in mouse BM. It
was also shown that DBC alone is selectively toxic to BM CFU-B formation at a 1 mg/kg
oral cumulative dose given over a five day period. In previous work, acute intraperitoneal
and oral administration of 50 mg/kg DMBA, (a DBC-like, synthetic PAH) suppressed BM
CFU-B and CFU-GM in mice (N’jai et al., 2010). The effect of the DBC following oral
administration on the BM has not been reported previously, nor has the toxicity of DBC at
the concentrations we examined been studied. . DBC toxicity is likely caused by the products
of its biotransformation (Siddens et al., 2012). DBC-dihydrodiol epoxide (DBCDE) is
formed through the action of two enzymes, CYP1B1 and epoxide hydrolase (Crowell et al.,
2014). DBC radical cation is formed through the action of peroxidases (Cavalieri et al.,
1991), and DBC-dione obtained through the breakdown of DBC-11, 12-dihydrodiol by
aldoketoreductases (AKR), (Courter et al., 2007). Thus, in addition to the formation of DNA
adducts by DBCDE, there is also potential redox cycling leading to the production of reactive
oxygen species (ROS) with resultant oxidative stress.
As+3 and its metabolites are known to be toxic. The biotransformation of As+3 by
arsenite methyltransferase (AS3MT) produces methylated species with varying toxicities,
including monomethylated forms such as monomethylarsonous acid (MMA+3) and
monomethylasonic acid (MMA+5), also dimethylated forms such as dimethylarsonous acid
(DMA+3) and dimetylarsonic acid (DMA+5) (Styblo et al., 2000; Aposhian et al., 2000).
MMA+3 is considered the most toxic arsenic species Styblo et al., 2000) and has been
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previously implicated by our lab in BM toxicity (Ezeh et al., 2014). Thus, an increase in the
formation of MMA+3 from in vivo As+3 is expected to produce more BM suppression than the
parent compound.
The combination of As+3 and DBC in vivo showed significant interactions at low
doses with slightly increased and selective suppression of CFU-B when 19 ppb, 30-day
drinking water As+3 was given in combination with 1 mg/kg, 5-day oral cumulative dose of
DBC . These doses did not significantly impact bone marrow cell recovery and viability in
mice, nor did they suppress BM cell differentiation when given individually. The observed
lack of significant effect on BM cell differentiation by individual exposures to these
compounds may be due to a number of reasons, including: insufficient bioactive metabolites
from the low doses administered, lack of induction of the enzymes responsible for their
bioactivation or a redirection of metabolites to other pathways not associated with toxicity. It
is, however, noteworthy that 1 mg/kg DBC showed a statistically significant suppression of
pre-B cells, but not CFU-GM when results were averaged for mice and expressed on a
pooled femur basis. The selective and significant suppression of CFU-B over CFU-GM
colony formation observed with 19 ppb As+3 and 1 mg/kg DBC combination, suggest that
there may be some interaction at these doses. Although we could not further define the
precise parameters responsible pertaining to the dose and time responses for interactions, we
know that As+3 and/or DBC metabolites could be involved in the toxicity observed. It is
possible that the presence of both compounds in the system could influence their individual
metabolism and resultant toxicity or lack of toxicity, such that ratio may also be important. It
is known that in the liver, As+3 alters the regulation of enzymes that are responsible for PAH
bioactivation (CYP1s), thereby decreasing PAH metabolite formation (Jacobs et al., 1999;
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Vernhet et al., 2003). Other studies (Spink et al., 2002; Bessette et al., 2005) also indicate
that As+3 diminishes the induction of the CYP1 enzymes. However, these studies were
conducted at higher concentrations of As+3 (micro molar ranges) than used in our present
work. As with DMBA (Gao et al., 2005), DBC is mostly metabolized by CYP1B1 in mouse
lymphoid tissues (Crowell et al., 2014). Therefore, if high doses of As+3 interfere with the
induction or activity of CYP1B1, this may explain the lack of interaction between As+3 and
DBC at the higher concentration of As+3.
For our in vitro studies, the combination of no-effect, low levels (0.5 and 5 nM) of
As+3 with no-effect, low levels (0.1 and 1 nM) of DBC and DBC-diol, produced significant
suppression of pre-B colonies that was greater than the individual parent compounds, but the
suppression did not always increase with higher concentration of chemicals as expected.
We show evidence of complicated dose responses in As+3 /DBC combination that
may be explained by the different direct and indirect effects of the individual compounds as
well as their metabolites and associated enzymes. As expected, 0.5 and 5 nM MMA+3 were
more potent than the same concentrations of As+3 in vitro. However, our studies demonstrate
significant MMA+3 interactions with DBC at the higher MMA+3 and DBC doses in vitro.
This suggests possible differences in the mechanisms of action between As+3 and MMA+3 in
their interactions with DBC in vitro. Therefore further studies are needed to understand the
reason for the lack of interaction between DBC and the higher doses/concentrations of As+3
and MMA+3 used in the present studies in murine BM.
In conclusion, we have observed that low doses of DBC selectively target the
lymphoid progenitors in mice, and that in vivo and in vitro there is a complex non-linear
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immunosuppressive interaction between As+3 and DBC. These findings are important
because these interactions occur at environmentally relevant doses and via normal
physiological routes of exposure.
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ABSTRACT
Our previously published data show that As+3 in vivo and in vitro, at very low
concentrations inhibit lymphoid, but not myeloid stem cell development in mouse bone
marrow. We also showed that the As+3 metabolite, monomethylarsonous acid (MMA+3) was
responsible for the observed pre-B cell toxicity caused by As+3. Interleukin-7 (IL-7) is the
primary growth factor responsible for pre-lymphoid development in mouse and human bone
marrow. Thus, we examined IL-7 signaling in a mouse pre-B cell line (2E8) that is dependent
on IL-7 for growth. We found that MMA+3, but not As+3 inhibited 2E8 cell proliferation at
concentrations that do not produce cytotoxicity. MMA+3, again in contrast to As+3, inhibited
IL-7 signaling in 2E8 cells as determined by a decrease in IL-7 induced STAT-5
phosphorylation. JAK phosphorylation was not affected by MMA+3. We found that the
induction of PAX5 gene expression, which is controlled by activated STAT5-associated
transcription factors that are induced by IL-7, was also selectively inhibited by MMA+3.
Since 2E8 cells lack the enzymes responsible for the conversion of As+3 to MMA+3 in vitro,
the results of these studies clearly show that MMA+3 is responsible for the lack of IL-7
signaling in 2E8 cells and offer a likely explanation for how As+3, which is metabolized to
MMA+3 in vivo, selectively targets the development of pre-lymphoid stem cells in mouse
bone marrow.
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INTRODUCTION
Arsenic exposure has been associated with many diseases including
immunosuppression, hematotoxicity, and carcinogenesis (Kozul et al., 2009; Li et al., 2010).
Trivalent inorganic arsenic (As+3) and its metabolite, monomethylarsonous acid (MMA+3),
have been associated with many toxicities in mammalian systems (Styblo et al., 2000).
Several studies have examined mechanisms associated with high dose acute exposures to
As+3 with the resultant DNA damage and alteration of DNA repair system (Wei et al., 2009;
Qin et al., 2012; Wang et al., 2013). In general, several factors including oxidative stress
(Flora, 2011), chromosomal aberration (Oya Ohta et al., 1996), inhibition of DNA repair and
PARP activity (Qin et al., 2012), and altered gene expression could collectively contribute to
As+3 toxicity.
Only a few studies have attempted to address mechanisms associated with As+3
toxicity from physiological, long- term, low dose, and environmentally relevant exposures.
Our lab previously observed that low doses of As+3 inhibit mouse bone marrow lymphoid but
not myeloid progenitor cell development in vivo (Ezeh et al., 2014). We attributed the in vivo
toxicity of As+3 to one of its primary organic metabolites, MMA+3, which is formed by the
liver and kidneys (Aposhian et al., 2000). We showed that MMA+3 inhibits pre-B
development from hematopoietic stem cells at concentrations that can be achieved with
environmental exposures.
For the selective targeting of mouse pre-lymphoid stem cells found in bone marrow
(BM), we hypothesized that As+3 and MMA+3 could modulate the BM microenvironment,
leading to alteration of IL-7 signaling which is critical for lymphoid cell formation and
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expansion. The cytokine, IL-7 has been shown to specify B-cell fate from the common
lymphoid to the pre-pro B stage (Kikuchi et al., 2005). It is also required for further
differentiation of B and T lineage cells. Because of the tremendous heterogeneity of cell
populations in the BM, we used 2E8 cells, an IL-7-dependent mouse pre-B cell line, to try to
elucidate the mechanism by which As+3 and MMA+3 could target the lymphoid progenitors in
the BM. Using similar concentration ranges of As+3 and MMA+3 that were previously studied
in BM primary cells, we conducted studies to determine whether As+3 and/or MMA+3 alter
IL-7 signaling in 2E8 cells.
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MATERIALS and METHODS
Reagents and chemicals
Hanks Balanced Salt Solution (HBSS) from Lonza (Walkersville, MD), Dulbecco’s
phosphate buffered saline w/o Ca+2 or Mg+2 (DPBS-), Iscoves Modified Dulbecco’s Medium
(IMDM) purchased from American Type Culture Collection (ATCC, Manassas, VA),
Penicillin/Streptomycin 10,000 (mg/ml)/10,000 (U/ml) (Pen/Strep) Life Technologies (Grand
Island, NY), β-Mecaptoethanol, Sigma Aldrich (St. Louis, MO), 1 mg/ml mouse IL-7 (mIL7) purchased from Peprotech, Fetal Bovine Serum (FBS) Atlanta Biologicals (Flowery
Branch, GA.), sodium arsenite (CAS 774-46-5, NaAsO2) purchased from Sigma-Aldrich (St.
Louis, MO); MMA+3 was the generous gift of Dr. Terry Monks at the University of Arizona
Superfund Center and the Southwest Environmental Health Science Center. STAT5 (clone
3H7, Cat. No. 9358), Phospho-STAT5 (Tyr694) (clone C11C5, Cat No. 9359), phosphoJAK1 (Tyr1022/1023) (Cat. No.3331), PAX5 (clone D19F8, Cat. No. 11849), and anti-rabbit
IgG –HRP secondary antibody (Cat. No. 7074) were purchased from Cell Signaling
Technology (Danvers, MA,). Purified mouse anti-JAK1 monoclonal antibody was obtained
from BD Transduction Laboratories (Franklin Lakes, NJ). Actin (clone I-19) goat polyclonal
IgG (Cat. No. sc-1616) and donkey anti-goat IgG-HRP secondary antibody (Cat.No. sc2020) were purchased from Santa Cruz Biotechnology (Dallas, TX).
Cell culture and treatments
The 2E8 cell line was purchased from ATCC and was first described by Ishihara et
al., 1991. 2E8 cells were grown and maintained in our laboratory following ATCC’s protocol
using complete medium consisting of IMDM 1 ng/ml mouse IL-7 (mIL-7), 20% FBS, 1 %
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Pen/Strep, and 0.05 µM β-mecaptoethanol. As+3 and MMA+3 were prepared in sterile water,
as 1000X stock solutions and used to treat 2E8 cell preparations at final concentration ranges
of 5 nM to 500 nM. Mouse IL-7 was prepared as 10 µg/ml stock solution and used to treat
2E8 cell preparations at a final concentration of 10 ng/ml in treatment medium or 1 ng/ml in
culture medium. Cells were first seeded at 5 x 105 cells/ml, in T75 flasks using complete 2E8
medium with 1ng/ml mIL-7 for three days, then washed twice in DPBS- to remove all mIL-7.
Cells were re-suspended in 2E8 medium without mIL-7 and treated with As+3 or MMA+3
overnight (~24 hrs.). Mouse IL-7 was re-introduced to treated cells at 10 ng/ml and cells
were incubated for an additional 30 minutes to evaluate signaling. Post incubation, cells were
harvested into 50 ml centrifuge tubes containing equal volume of ice cold DPBS- and washed
twice by centrifugation at 400 x g, 4oC for 10 minutes. Washed cells were used for Total
RNA extraction or stored at -80oC for protein extraction and immunoblotting.
Cell proliferation and viability
To determine cell proliferation and IL-7 dependence, 2E8 cells were grown at starting
concentrations of 2.5 x 105 cells/ml in 2E8 medium with or without mIL-7 for 5 days. IL-7
was not replenished, and medium was not changed during the 5 day period. Cell counts were
obtained in triplicate for each sample each day for 5 days, using the Nexcelom Cellometer
Auto 2000 cell counter. Viability counts were also obtained using the same instrument with
Acridine Orange/Propidium Iodide (AO/PI) staining. To test the sensitivity of 2E8 cells to
treatment, proliferation and viability were also determined daily during the 5-day period for
cells exposed to different concentrations of As+3 or MMA+3 in complete medium.
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2E8 protein extraction and immunoblotting analyses
Treated and washed cell pellets were re-suspended at 2 x 105 cells/µl in radioimmune
precipitation assay (RIPA) buffer (50 mM Tris, 150 mM sodium chloride, 0.5 % sodium
deoxycholate, 1 % Triton X-100, 0.1 % sodium dodecyl sulphate (SDS), pH 8.0) with added
protease inhibitors including one 25 mg protease inhibitor mini tablet (Roche Diagnostics), 1
% sodium orthovanadate (Na3VO4), and 200mM phenylmethylsufonyl fluoride
(PMSF).Samples were sonicated for 10 seconds on ice and centrifuged at 20,000 x g. Total
protein (the supernatant) from each sample was quantified using the Bicinchoninic Acid
(BCA) protein assay procedure (Pierce, Thermo Scientific). The protein extracts were
resolved by electrophoresis on Criterion TGX precast gels (Bio-Rad) and transferred to
nitrocellulose membranes. Antibodies against STAT5, pSTAT5, JAK1, pJAK1 or PAX5
were used to identify these proteins by immunoblotting. Using the Super Signal West Femto
Maximum Sensitivity Substrate kit (Thermo Scientific), protein bands were resolved on the
FLuorChem R ProteinSimple imager and analyzed with Image J (1.48v) software. Protein
molecular weights were determined using the Precision Plus Protein Pre-stained Standards
(Bio-Rad).
Total RNA isolation
Total RNA was isolated from treated and washed triplicate samples using RNeasy
Mini Kit and Shredder (Qiagen, Valencia, CA.) following manufacturer’s instructions.
Briefly, treated and washed cells were pelleted in 15 ml centrifuge tubes, resuspended in 600
µl RLT buffer (contained in kit) with 10 µl/ml ß-mercaptoethanol and mixed by vortex. Each
sample was transferred into a labeled QIA Shredder column and centrifuged at 20000 x g for
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2 minutes. The isolation process was completed by following subsequent steps in the kit
instructions, with final elution of total RNA using 50 µl, nuclease-free water. Total RNA
concentration was calculated using the Nanodrop procedure for RNA quantitation. Results
ranged from 3.7 - 7.5 µg/sample.
Synthesis of cDNA from total RNA
cDNA samples were synthesized from the isolated total RNA by reverse transcriptase
(RT) reaction using High Capacity cDNA Archive Kit (Applied Biosystems) according to kit
instructions. A 2X Master mix (MM) was prepared with 10X buffer, 25X dNTP, 10 Random
primers, nuclease-free water and multiscribe and was placed into each PCR tube. The
samples were placed in PCR tubes containing equal volumes of the 2X MM and centrifuged
for ~10 seconds before incubating on to the Thermal Cycler DNA Machine set at 25oC for 10
minutes, 37oC for 2 hours. The cDNA samples were stored at -80oC for later use.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Synthesized cDNA was used as template to amplify PAX5 gene and measure the fold
change in induction of PAX5 (Applied Biosystems, Assay ID: Mm00435501_m1). Using
cDNA template (from 18 ng total RNA) and the TaqMan Universal PCR Master Mix
(Applied Biosystems), the PCR reactions were set up for the detection and quantification of
PAX5 mRNA. GAPDH was used as the endogenous housekeeping gene and the control or
untreated samples as the calibrator. The parameters for the PCR reactions thermal profile
were Activation 50oC for 2 minutes, 95oC for 10 minutes, 95oC for 15 seconds, and 60oC for
1 minute for 40 cycles. The qRT-PCR was carried out using the 7900 HT system (Applied
Biosystems) with 384-well block. For relative mRNA quantification, we used the
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Comparative CT method. The ΔCT values between the test and housekeeping genes and the
fold difference (2-ΔΔCT) in the expressions for all the samples were determined and plotted as
a bar or line graph in Sigma Plot.
Statistics and Data Analysis
All data were analyzed with SigmaPlot version 12.0, using one way analyses of variance
(ANOVA) and Dunnetts t-test where applicable, for the determination of differences between
control and treatment groups. For immunoblotting analysis, samples were treated and ran in
triplicates as shown on the blots. Image J (1.48v) software (NIH download from website:
http://rsb.info.nih.gov/ij/) was used to obtain band intensities for treatment and control
samples.
For the qRT-PCR studies, samples were treated in triplicate and each replicate was
ran in triplicate to obtain 9 data points per sample. The log2 2-ΔΔCt ratios (samples normalized
to GAPDH and compared to control) were calculated from the average of samples run in
triplicate. These ratios were compared to control via analysis of variance (ANOVA) with
post-hoc comparisons using Dunnett’s method to control for multiple comparisons.
Differences were considered significant if the p-value for a given comparison was less than
the type I error rate α=0.05.
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RESULTS
The mouse 2E8 pre-B cell line is IL-7 dependent
Mouse 2E8 cells are a cloned and differentiation-limited pre-B cell line that maintains
its responsiveness to IL-7 (Ishihara et al., 1991). To determine the suitability of 2E8 for the
proposed IL-7 signaling studies, we first determined the IL-7 dependence of the cells grown
in culture. As shown in Figure 4.1A, 2E8 cells were found to have an absolute growth factor
dependence on IL-7. When IL-7 was removed from the media, 2E8 failed to grow and began
to lose cell viability measured using AO/PI, 4 days after seeding cultures.
Comparative effects of As+3 and MMA+3 on 2E8 cell growth
As+3 did not modify the growth of 2E8 cells in the presence of IL-7 except at the high
(500 nM) concentration (Figure 4.1B). However, MMA+3 was found to inhibit cell
proliferation and viability at concentrations as low as 50 nM on days 3-5 (Figure 4.1C). 500
nM As+3 also inhibited proliferation and viability on days 3-5 (Figure 4.1B). The inhibition
of proliferation and viability observed for As+3 and MMA+3 were comparable to that
observed in the absence of IL-7. Since IL-7 was not replenished, and the medium was not
changed during the 5-day culture period, we thought that the effects of MMA+3 and high
concentration As+3 could be due to alterations in IL-7 action. This effect was not seen with
lower levels of As+3 and MMA+3. We therefore postulated that MMA+3 and As+3 were
interfering with IL-7 signaling.
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Figure 4.1. Five day cell proliferation (cells/ml) and viability (%) by automated cell counter
and AO/PI staining. Cell culture in medium with or without 1 ng/ml IL-7 [A]; in medium
containing IL-7 and different concentrations of As+3 [B]; in medium containingIL-7 and
different concentrations of MMA+3 [C]. Error bars are + SD.
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MMA+3 decreases STAT5 activation in 2E8 cells, but does not inhibit JAK1 activation
IL-7 signals cell growth and differentiation through a STAT5 pathway involving
phosphorylation of tyrosine 694 (Clark et al., 2014). We found that STAT5 activation was
dependent on the presence of IL-7, as the levels of STAT5 phosphorylation were almost
undetectable when cells were incubated overnight (~24 hr) in the absence of IL-7 (Figure
4.2A and 4.2C). To examine the effects of As+3 and MMA+3 on STAT5 activation, we
analyzed total STAT5 protein expression as well as the phosphorylation of STAT5 via
Western blots. MMA+3 decreased the ratio of phosphorylated STAT5 to total STAT5
protein. Thus, MMA+3 inhibited IL-7-induced STAT5 phosphorylation in a concentrationdependent manner (5-500 nM) when compared with total STAT5 protein, as determined by
the density of band images obtained in triplicate (Figure 4.2A and 4.2C). STAT5 signaling
was IL-7 dependent and 50 nM MMA+3 was unable to modify STAT5 phosphorylation in the
absence of IL-7. The 500 nM concentration of MMA+3 almost abolished total STAT5 levels,
(Figure 4.2B and 4.2C). Therefore, even though 500 nM MMA+3 showed comparable
proliferation (live cell count) and percent viability (AO/PI stain), this concentration could
involve additional mechanisms than just IL-7 signaling.
As+3 does not inhibit STAT5 phosphorylation
In contrast to MMA+3, As+3 had no effect on total STAT5 or pSTAT in the
concentration range of 5-500 nM (Figure 4.3A, 4.3B and 4.3C). These results clearly
demonstrate that the effects of arsenic on IL-7 signaling in vitro is associated with MMA+3
and not As+3.
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Figure 4.2. Effects of MMA+3 on STAT5 activation in 2E8 cells. Phosphorylated STAT5
compared to STAT5 total protein in MMA+3- treated cells [A], total STAT5 protein band
intensity normalized to Actin band intensity [B], blot of pSTAT5, total STAT5, and Actin
for MMA+3- treated cells [C]. Cells were incubated overnight (~24 hrs),in medium without
IL-7, but containing 0-500 nM MMA+3, then washed twice and treated with 0 ng/ml or 10
ng/ml IL-7 and incubated for 30 minutes. Error bars are + SD. *Significantly different
compared to control.
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Figure 4.3. Effect of As+3 on STAT5 activation in 2E8 cells (by Western).
Phosphorylated STAT5 compared to STAT5 total protein [A], total STAT5 protein
band intensity normalized to Actin band intensity [B], blot of pSTAT5, total STAT5,
and Actin for As+3-treated cells [C]. Cells were incubated overnight (~24 hrs) in
medium without IL-7, but containing 0-500 nM As+3, then washed twice and treated
with 0 ng/ml IL-7 or 10 ng/ml IL-7 and incubated for 30 minutes. Error bars are + SD.
*

Significantly different compared to control.
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MMA+3 and As+3 do not inhibit JAK1 activation
Activation of JAK1, the immediate upstream activator of STAT5, was also examined
under identical conditions used to evaluate the effects of MMA+3 and As+3 on STAT5
activation. MMA+3 did not inhibit JAK1 phosphorylation (Figures 4.4A and 4.4C), and may
have produced a small increase in total JAK1 level at 50 nM, compared to pJAK1 (Figures
4.4A and 4.4B). The 500 nM concentration of MMA+3 did inhibit total JAK1 (Figure 4.4C)
and pJAK1 levels (Figure 4.4A), as it did for STAT5 and pSTAT5. Thus we decided to
examine effect of lower concentrations of MMA+3 on the induction of PAX5, a STAT5
responsive gene. As+3 at concentrations of 5-500 nM did not inhibit JAK1 phosphorylation or
total JAK1 (Figures 4.5A, 4.5B and 4.5C).
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Figure 4.4. Effect of MMA+3 on JAK1 activation in 2E8 cells. Phosphorylated JAK1
compared to JAK1 total protein in MMA+3- treated cells [A], total JAK1 protein band
intensity normalized to Actin band intensity [B], blot of pJAK1, total JAK1, and Actin for
MMA+3- treated cells [C]. Cells were incubated overnight (~24 hrs) in medium without IL7, but containing 0-500 nM MMA+3, then washed twice and treated with 0 ng/ml or 10
ng/ml IL-7 and incubated for 30 minutes. Error bars are + SD. *Significantly different
compared to control.
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Figure 4.5 Effect of As+3 on JAK1 activation in 2E8 cells (by Western). Phosphorylated
JAK1 compared to JAK1 total protein [A], total JAK1 protein band intensity normalized
to Actin band intensity [B], blot of pJAK1, total JAK1, and Actin for As+3-treated cells
[C]. Cells were incubated overnight (~24 hrs) in medium without IL-7, but containing 0500 nM As+3, then washed twice and treated with 0 ng/ml IL-7 or 10 ng/ml IL-7 and
incubated for 30 minutes. Error bars are + SD. *Significantly different compared to
control.
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PAX5 message and protein were inhibited by MMA+3 but not by As+3
As an additional test of altered pSTAT5 activity produced by MMA+3, we examined
the induction of PAX5, a pSTAT5 responsive gene associated with lymphoid differentiation
(Liu et al., 2014). With IL-7 in the culture medium, we found a small but significant increase
in the PAX5 mRNA levels in 2E8 cells compared to the IL-7 –deficient culture. The
induction of the PAX5 gene was inhibited by MMA+3 in a concentration-dependent manner
in the concentration range of 100-200 nM (Figure 4.6A). These concentrations are slightly
higher than those required to inhibit STAT5 phosphorylation; however, it is clear that PAX5
regulation is not as directly dependent on IL-7 signaling as STAT5. As+3 did not affect PAX5
mRNA expression. We also examined PAX5 protein expression (Figure 4.6B). MMA+3
decreased PAX5 protein expression at 100-200 nM concentrations, but As+3 had no effect on
PAX5 protein expression at concentrations up to 500 nM.
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Figure 4.6. Fold change in PAX5 induction in As+3 or MMA+3-treated cells (by RTqPCR) [A]. Effect of As+3 or MMA+3 on PAX5 total protein (by Western) [B]. Cells
were incubated overnight (~24 hrs) in medium without IL-7, but containing 0-500 nM
As+3, or 0-200 MMA+3, then washed twice and treated with 0 ng/ml IL-7 or 10 ng/ml IL7 and incubated for 30 minutes. Error bars for fold change in PAX5 are + SD.
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DISCUSSION
Numerous diseases including cancers, vascular diseases, lung diseases, and diabetes
have been linked to environmental exposures to As+3 in drinking water and food (Argos et
al., 2010, 2014; Chen et al., 2003; Chen Y, et al., 2011; Navas-Acien et al., 2005, 2006).
While numerous mechanisms of As+3 toxicity in cells have been proposed, most studies have
used extremely high levels of As+3 for in vivo and in vitro studies. At micro molar
concentrations, As+3 is well known to produce oxidative stress that impacts many cellular
pathways (Kitchin and Conolly, 2010; Flora et al., 2011). Previous studies have examined
DNA damage and repair pathways that are associated with the genotoxicity of As+3 (King et
al., 2012; Cooper et al., 2013). However, there have been few studies that have examined
non-genotoxic pathways associated with cell signaling.
Immune and inflammatory diseases could play a role in many chronic diseases
associated with arsenic exposures. Prenatal arsenic exposures have been linked to immune
suppression and altered lymphoid cell development (Ahmed, et al., 2012; Nadeau et al.,
2014). We have previously observed selective targeting of murine BM lymphoid progenitors
by extremely low doses of As+3 in vivo administered through physiologically relevant route,
and MMA+3 in vitro at environmentally relevant levels of exposure (Ezeh et al., 2014).
MMA+3 is formed through a series of metabolic reactions via the action of arsenite-3methyltransferase (AS3MT), which is expressed in the liver and a few other extrahepatic
tissues (Aposhian et al., 2000). AS3MT is not found at appreciable levels in lymphoid cells.
Thus, for in vitro studies, it was necessary to add MMA+3 directly to cell cultures to observe
its effects on lymphoid cell function.
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It is important to understand the effects of MMA+3 on lymphoid cells because they
are very sensitive and are exposed to both As+3 and MMA+3 through blood circulation. Also,
because AS3MT is polymorphic in humans and has been causally linked to many arsenicinduced environmental diseases (Pierce et al., 2012), it may play a role in differences in interindividual toxicities in human populations.
The present studies assessed the role of As+3 and one of its key metabolites, MMA+3,
on lymphoid progenitor cell differentiation. Beginning from the Pre-pro B to the large B cell
stage, lymphoid progenitors express the IL-7 receptor alpha (IL-7Rα, CD127) and respond to
IL-7 (Clark et al., 2014; Peschon, et al., 1994). IL-7 is a cytokine growth factor produced by
the BM stromal cells (Fry and Mackall, 2001) and it is associated with proliferation, survival,
and differentiation of B and T cells (Corfe et al., 2012). Humoral immune responses, which
we have shown are extremely sensitive to in vivo As+3 exposure (Ezeh et al., 2014), utilize
the ability of the lymphoid progenitors to expand following antigen challenge. Inhibition of B
cell differentiation and proliferation by environmental pollutants can negatively impact the
humoral immune responses, leading to decreased immunity and increased susceptibility to
disease.
The IL-7R consists of the IL-7Rα (CD127) which is specific for IL-7 ligand, and the
IL-7Rγc chain (CD134) usually shared by other cytokines. Early B cells express CD127 for
IL-7 signaling. Upon IL-7 binding to CD127 in a B cell, a cascade of phosphorylation
initially begins with the receptor-associated Janus Kinases 1 and 3 (JAK1 and JAK3), and
results in the phosphorylation of intracellular Signal Transduction and Activator of
Transcription 5 (STAT5) molecules on tyrosine residues Tyr694 and Tyr699. These
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phosphorylated STAT5 molecules dimerize and translocate to the nucleus to drive the
transcription of genes responsible for commitment maintenance, further differentiation,
proliferation, and survival of the B lineage cells. It has been shown that deletion of total
STAT5 protein (STAT5a/5b) in cultures of fetal liver cells inhibited IL-7- induced lymphoid
expansion (Dai et al., 2007). Although STAT5 activation could occur with several other
cytokines, it is predominantly activated by IL-7 (Snow et al., 2002). In our cloned pre-B 2E8
cell system, STAT5 is exclusively activated by IL-7. Downstream of STAT5, the
transcription factor, early B factor (EBF) in concert with E2A upregulate PAX5 gene
expression (O’Riordan and Grosschedl, 1999). Whereas IL-7 and STAT5 signaling control
the stepwise order of immunoglobulin gene rearrangement and also survival of B cells
(Malin et al., 2010). Studies show that PAX5 is responsible for initiating and maintaining B
lineage commitment (Mikkola et al., 2002). Due to the observed minimal levels of PAX5 in
pre-pro B cells (Nutt et al., 1999; Rolink et al., 1999), it has been suggested that pre-pro B
cells are not yet irreversibly committed to the B cells lineage, and do retain the potential to
re-commit to T, NK, or DC-lineage. PAX5 protein has also been shown to repress
commitment to the myeloid lineage. There is a complex relationship between STAT5 and
PAX5. The promoter region of PAX 5 contains a STAT5 binding motif (Goetz et al., 2005).
STAT5 therefore maintains survival of B cells during the transition from the CLPs to the proB cell stage (Malin et al., 2010). Inhibition of STAT5 phosphorylation and PAX5 gene
expressions could therefore lead to a diversion from the B lineage commitment and
unbalanced immune responses.
Normal development of B and T cells rely on IL-7 signaling. Abnormal B and T cell
function is associated with immunodeficiency which is marked by increased susceptibility to
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infections, cancers, and other diseases. Many studies show that As+3 exposure produces
immunosuppression and increased susceptibility to infections in children and adults (Burchiel
et al., 2014; Nadaeu et al., 2014).The presence of MMA+3 in urine of individuals exposed to
As+3 has been noted (Aposhian et al., 2000). MMA +3 is known to be associated with
irreversible transformations that lead to disease. As+3 is also known to increase the
genotoxicity of other carcinogens by inhibiting enzymes involved in DNA repair through
various mechanisms, including the production of reactive oxygen species (Wang et al., 2013)
and interaction with zinc finger proteins (Zhou et al., 2013).
This study shows that MMA+3 inhibited phosphorylation of STAT5 at low (5-50 nM)
concentrations that are not cytotoxic to 2E8 cells. MMA+3 did not inhibit JAK1 activation,
and also had no effect on IL-7Rα (CD127) expression, data not shown. The selective
inhibition of STAT5 activation suggests that MMA+3 could be upregulating a STAT5specific phosphatase or inhibitor. Protein inhibitors of activated stats (PIAS), also known as
E3-SUMO ligase, reside in the nucleus and are known to specifically deactivate
phosphorylated STATs that translocate to the nucleus (Arora et al., 2003; Chung et al., 1997;
Liu et al., 2001). Furthermore, other proteins like the cytokine inducible SH2-containing
protein (CIS), a suppressor of cytokine signaling (SOC), and phosphotyrosine phosphatases
(PTPs) could dephosphorylate already phosphorylated STAT5; however, these proteins are
not specific for STATs. We therefore believe that MMA+3, but not As+3, recruits PIAS upon
activation of STAT5. Further studies will be necessary to confirm this speculation. We do not
know the precise molecular structures of JAK1 and STAT5. However, we believe that 500
nM MMA+3 but not As+3 could target the thiol groups in the active site of these proteins
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resulting in the observed toxicity, and that the lack of phosphorylation at this level may be
due to toxicity to the total proteins.
Induction of the STAT5 responsive gene, PAX5 was also suppressed by MMA+3, but
not by As+3. PAX5 protein levels were also reduced by MMA+3 in concentration-dependent
manner in 2E8 cells. The different responses of STAT5 and PAX5 proteins to As+3 and
MMA+3 could be due to a number of reasons, including differences in the cysteine residue
content of the peptides, and the presence or absence of other thiol-containing amino acids in
these proteins. As+3 is known to bind peptides that contain three (C3) and four (C4) cysteine
residues, whereas MMA+3 is capable of binding peptides containing two (C2) or more
cysteine residues (Zhou et al., 2011; Zhao et al., 2012). Thus, MMA+3 has a different
spectrum of action than does As+3.
In summary, our studies demonstrate important differences between the
immunotoxicity of MMA+3 and As+3 on lymphoid cells. We demonstrate a new mechanism
by which MMA+3 can inhibit pre-lymphoid cell development through inhibition of IL-7
signaling pathways. These effects occur at extremely low concentrations that may not
involve a generalized oxidative stress and illustrate the importance of non-genotoxic
pathways in the action of arsenic.
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CHAPTER 5
GENERAL DISCUSSION AND SIGNIFICANCE
Our laboratory has previously shown in murine spleen cell models that most of the
immunotoxicity of genotoxic PAHs, such as DMBA, result from their ability to metabolize
PAHS to form reactive metabolites that covalently bind to DNA and activate ATM/ATR
signaling pathways, resulting in p53-dependent inhibition of cell cycling (Gao et al., 2007,
2008). Proliferation is required for activation of lymphocytes. Therefore, such effects result
in immunosuppression.
DNA adducts are repaired by NER and BER pathways (Crew et al., 2007; Gunz et al.,
1996; Yu et al., 2012). Low dose exposures of cells to PAHs form a low level of adducts that
are likely repaired without damage to the immune system; however, when DNA repair is
compromised, we believe that these low dose exposures can result in significant
immunosuppression. Therefore, we postulated that agents like As+3 that are known to inhibit
NER and BER pathways (Ebert et al., 2011; Piatek et al., 2008), would block the repair of
lymphoid adducts resulting in low dose immunosuppression by genotoxic PAHs. Previous in
vitro studies in spleen cells supported this hypothesis, where it was found that DMBA, DBC,
and other PAHs produced synergistic immunosuppression of the T-dependent antibody
response (TDAR) in murine spleen cells (Li et al., 2010). Most of what is known about DBC
is associated with its genotoxicity (Amin et al., 1995; Platt et al., 2004). As+3 has been
implicated in the enhancement of the genotoxicity of carcinogens, including PAHs and
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ultraviolet radiation (Hartwig et al., 2003; Wang et al., 2013) by inhibiting DNA repair
(Cooper et al., 2013; Klein et al., 2007; Rossman et al, 2004).
BM stem cells play a critical role in the formation of lymphoid progenitors that are
important in maintaining host immunity. Patients receiving cytotoxic drugs for cancer are
immunosuppressed and often have serious morbidity and mortality resulting from increased
infections (Mackall et al., 1994). The maximum tolerated dose for most cancer
chemotherapeutic agents is often defined by BM toxicity. Therefore, it is somewhat
surprising that more studies on characterizing the effects of environmental agents, such as
PAHs, on mouse and human BM have not been performed. The limited amount of work that
has been previously performed have used conditions that are neither physiologically or
environmentally relevant (i.e., single high dose exposure given by the i.p, route, (Galvan et
al., 2003, 2006; Heidel et al., 1998, 1999, 2000; N’jai et al., 2010; Page, et al., 2003).
Based on the knowledge of the genotoxic action of DMBA, it was decided to evaluate
the hypothesis that As+3 may increase the immunotoxicity of PAHs in vivo. Previous work
was performed in vitro with DMBA, BaP, and DBC (Li et al., 2010), knowing that many
factors have the potential to influence these interactions in vivo. DBC, an environmentally
relevant PAH (Mumford et al., 1995) that has been found to suppress spleen cells in vitro
(Lauer et al., 2013), but has not been characterized for its effects on BM, was chosen. DBC
was chosen over DMBA because DMBA is synthetic and not found in the environment.
However, like DMBA, DBC is genotoxic and requires metabolic activation by P450
CYP1B1 to form adducts (Buters et al., 2002; Luch et al., 1998). CYP1B1 was found to be
critical for DMBA suppression of pre-B cell colony formation (Heidel et al., 1998).
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In several studies, an increase in susceptibility to infection following exposure to
arsenite has been observed (Farzan et al, 2013; Kozul et al., 2009; Potera et al, 2013; Spivey
et al, 2011). Thus, three Aims were developed to characterize the effects of As+3 in vivo and
in vitro on murine BM cells, to evaluate the combined effects of As+3 and DBC in vivo and in
vitro, and finally to explore the mechanisms by which As+3 and associated metabolites
produce their effects on murine BM. The focus was on much lower doses of As+3 than have
been previously studied in order to make predictions about the likely environmental
relevance of our findings.
SUMMARY OF AIM 1 FINDINGS AND THEIR SIGNIFICANCE
In addressing the effects of low levels of exposure to As+3 in vivo, initial dose-range
studies were performed with sodium arsenite in drinking water for 30 days at the levels of 75
and 300 ppb. These doses were chosen based on the work of Kozul et al. (2008), who found
that 30 day exposure at 200 ppb resulted in significant morbidity and mortality to mice
exposed to an influenza virus.
In this study, a novel observation that mouse BM lymphoid (CFU-B) progenitor cells
activated by IL-7 were sensitive to suppression by As+3 at a concentration of 300 ppb,
whereas the myeloid progenitors (CFU-GM) activated by GM-CSF were not. At the 300 ppb
dose, there was also a slight but statistically significant (p < 0.05) decrease in BM cell
recovery from femurs of exposed mice (Figure 2.3a; Table 2.1). For these initial studies,
spleen cell TDAR responses were also examined and they were suppressed at 75 and 300 ppb
exposure levels. Thus, there is differential toxicity of As+3 on different lymphoid organs, and
these observations are currently being followed by other investigators in our lab. The
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lymphoid progenitor suppression observed in this study occurred without any change in the
markers of non-committed or stem cell populations or the hematopoietic and mesenchymal
stem cells after 30 days exposure to As+3. Cell surface markers on B cells in the spleen were
also unaltered even though TDAR was suppressed.
For in vitro studies, a series of novel observations were made pertaining to the
relative lack of effects of As+5 on murine BM, the selective toxicity of As+3 on BM lymphoid
progenitors, and the extremely potent effects of MMA+3 on lymphoid progenitors (pre-B, but
also likely to be observed in pre-T cells). MMA+3 was included in the in vitro studies because
there are many papers that show that it is formed in vivo from As+3 in the presence of
AS3MT (Aposhian et al., 2000; Chen et al., 2011; Hirano et al., 2004; Styblo et al., 2000).
AS3MT is expressed predominantly in the liver and kidney, and the methylation of arsenic
was initially thought to be important for rapid elimination of arsenicals from the body. In fact
some investigators have performed clinical studies to try to hasten the elimination of arsenic
by increasing metabolism to methylated species (Gamble et al., 2007). However, it is now
known that MMA+3 has significant toxicological effects, and it may be responsible for many
of the toxicities seen with As+3 (Chen et al., 2011; Drobna et al., 2009; Styblo et al., 2000)
There is a strong correlation between AS3MT levels and cancer outcomes in several
epidemiologic studies (Pierce et al., 2013). It is highly significant that we found that MMA+3
produced low dose selective suppression of CFU-B colony formation as it suggests, but does
not prove, that the toxicity of As+3 to murine BM may in part be due to MMA+3. Further, in
vivo studies using, for example, AS3MT null mice, would be needed to provide further
evidence (Chen et al., 2011; Drobna et al., 2009).
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Given the low doses and/or concentrations of As+3/MMA+3 at which pre-B cells were
selectively targeted, important questions were raised as to the potential mechanism(s) of
these effects. This idea was fully explored in Aim 3 following completion of studies to
examine As+3 and PAH (DBC) interactions evaluated in Aim 2.
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SUMMARY OF AIM 2 FINDINGS AND THEIR SIGNIFICANCE
The immunosuppressive properties of certain forms of arsenic (Burns et al., 1991;
Harrison and McCoy, 2001; Szczeklik et al., 1994) and PAHs (Burchiel et al., 1988, 1990;
White Jr., 1985) at high doses have been established. The PAH used in this study is DBC,
which is naturally occurring and has been shown to be comparable in toxicity to the highly
potent but synthetic DMBA (Cavalieri et al., 1991). Even though DMBA has been used as a
model to demonstrate the carcinogenicity and overall toxicity of PAHs, it is not
environmentally relevant like DBC. However, DBC’s suppression of TDAR in spleen cells
in vivo (Lauer et al., 2013) and in vitro (Li et al., 2010) provided a clue that low levels could
synergize with low levels of As+3 to produce immunosuppression in the BM. Synergistic
immunosuppression of DBC and As+3 was indeed found in spleen cells (Li et al., 2010) in
vitro.
Although exposure to environmental pollutants is usually in combination, only a few
studies address combination exposures to these pollutants. In contrast to the effect observed
for As+3 and UV radiation exposure (Wang et al., 2013), this study showed that As+3
interaction with DBC at environmentally relevant doses is non-linear and may be dependent
on dose and ratio of As+3 to DBC. Also, in an effort to establish no-effect doses of chemicals,
this study showed for the first time that very low levels (1 mg/kg, 5-day cumulative dose) of
DBC is selectively toxic to the lymphoid progenitors in the BM.
In vivo, As+3 doses as low as 19 and 75 ppb did not produce immunosuppression in
murine BM following 30 day drinking water exposure (Figure 2.2). However, upon
concomitant exposure to 1 mg/kg, 5 day cumulative dose of DBC, there is interaction with
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the 19 ppb As+3 when CFU-B counts are expressed on per million cell basis (Figure 3.2a) and
immunosuppression from both 19 and 75 ppb when CFU-B counts are expressed on per
femur basis (Figure 3.2b). The expression of the results on per femur basis takes into
consideration the biological and/or experimental BM cell loss that could have occurred in
each animal due to exposure or during experiment. Increased doses did not necessarily
produce increase in toxicity.
The in vitro studies confirmed the non-linear and complex nature of As+3 and DBC
interactions. The combined exposure of murine primary BM cells, to very low, no-effect
concentrations of As+3 with no-effect concentrations of DBC and DBC-diol in vitro,
suppressed CFU-B colonies in a complex non-linear pattern as seen in vivo (Figure 3.3).
Knowing that the metabolites of both compounds may be involved in the reactions, a detailed
study of the metabolites and the enzymes responsible for the biotransformation will be
important. Whereas the enzyme, AS3MT is responsible for As+3 biotransformation through a
series of methylations and demethylations, the enzyme CYP1B1 and microsomal epoxide
hydrolase (mEH) are known to catalyze the metabolism of DBC. It was previously suggested
that As+3 influences PAH metabolism by altering the regulation of the CYP1 enzymes
(Jacobs et al., 1999; Vernhet et al., 2003). It will be necessary to examine the influence of
one chemical on the metabolism of the other, including the induction and activity of its
enzyme in cases of combined exposure.
The interactive suppression of the lymphoid progenitors could be either by genotoxic
or non-genotoxic mechanisms, or a combination of both. Our studies showed that MMA+3
was more effective in suppressing pre-B cells in vivo and in vitro. We know that MMA+3 can
inhibit DNA repair leading to cell death (Piatek et al., 2008). However, we have seen an
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inhibition of IL-7-induced pre-B cell formation in mouse BM at doses/concentrations that are
not cytotoxic was observed in this study. This lead to the decision in Aim 3 to evaluate the
effects of As+3 and MMA+3 on IL-7 signaling, which represents an important, potential nongenotoxic mechanism of action.
SUMMARY OF AIM 3 FINDINGS AND THEIR SIGNIFICANCE
The studies performed in vitro in Aims 1 and 2 implicate MMA+3 as important As+3
metabolite that may be responsible for inhibition of pre-B cell formation in murine BM. Aim
3 directly addressed the potential mechanism of action of MMA+3 utilizing a mouse pre-B
cell line (2E8) that is IL-7 dependent. This cell line was chosen because it is a pure clone,
which is advantageous for biochemical studies. Mouse BM, on the other hand, is extremely
heterogeneous and makes data interpretation difficult. It was also found that the mouse 2E8
cells had minimal JAK/STAT signaling in the absence of IL-7, and is considered an
appropriate and sensitive model to evaluate the effects of As+3 and MMA+3.
Results clearly showed for the first time that MMA+3 at non-cytotoxic (5-50 nM)
concentrations inhibited IL-7 dependent cell growth and signaling. As+3 only inhibited IL-7
cell growth and signaling at high concentrations (500 nM) in overnight incubations. The
inhibition of IL-7 signaling occurred at the level of inhibition of STAT5 phosphorylation, but
it did not interfere with JAK1 activation. These results suggest a novel mechanism of
inhibition which further studies will need to explore (see below). It is interesting that As+3
does not affect STAT5 phosphorylation, and we know from preliminary PCR studies that
2E8 cells do not express significant, if any AS3MT. Thus, the in vivo formation of MMA+3
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by AS3MT could contribute to inhibition of IL-7 signaling in mouse bone marrow, but
further studies will need to be performed to resolve this point.
Further support for the mechanism of inhibition of STAT5 phosphorylation by
MMA+3 was obtained by examining the PAX5 gene promoter and protein which are induced
by pSTAT5. The results showed that MMA+3 inhibited PAX5 gene induction and protein
expression, but this gene and protein were not entirely turned off in the absence of IL-7 in
control cells. The lack of complete IL-7 dependence make this gene and protein an imperfect
model to study MMA+3, but the literature suggests that this is the most sensitive gene to
study. Nevertheless, the inhibitions at both the gene activation and protein level for PAX5
support our underlying hypothesis.
MMA+3 could possibly interact with STAT5 directly to prevent phosphorylation, or it
could interact indirectly by modulating other enzymes. One or more of several processes
could be involved in the selective dephosphorylation of activated STAT5 caused by MMA+3,
including: the involvement of protein inhibitors of activated STATs (PIAS), also known as
E3-SUMO protein ligase; induction of cytokine inducible SH2 containing (CIS) proteins,
which are suppressors of cytokine signaling (SOCs); and/or induction of protein tyrosine
phosphatases (PTPs). Unlike the SOCs and PTPs, PIAS reside in the nucleus and are specific
for activated STATs which translocate to the nucleus. They also require activation of STATs
for interaction (Arora et al., 2003; Chung et al., 1997; Liu et al., 2001). Since
phosphorylation of JAK1 was not inhibited, nor was the unphosphorylated STAT5 protein, it
is reasonable to postulate that PIAS may be responsible for the selectivity in MMA+3
phospho-inhibitory effects. Immunoprecipitation and immunoblotting analysis to check for
SUMO-attachment to activated STAT5 in MMA+3-treated and control cells, and use of
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phosphatase inhibitors with treatments, would have been helpful to determine by what
mechanism MMA+3 inhibits STAT5 but not JAK1 activation. Also, STAT5 molecules are
phosphorylated on Tyr694 (for STAT5a) and Tyr699 (for STAT5b). On a linear scale, these
sites are very close to the DNA binding domain or active site of the proteins and would most
likely be affected by MMA+3 binding to thiol groups in the active site. In contrast, JAK1
phosphorylation occurs on Tyr1022 and Tyr1023, which are farther from the active site of the
protein and less likely to be affected by MMA+3 binding to active site thiols. Overall, this
study shows for the first time that MMA+3, not As+3, inhibits IL-7-induced STAT5
phosphorylation and decreases the transcription of important lymphoid lineage-specific
genes.
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OVERALL REFLECTIONS ON THE SIGNIFICANCE OF THESE STUDIES AND
POTENTIAL AREAS FOR NEW STUDIES
These are the first studies to implicate a selective toxicity of MMA+3 on lymphoid
stem cells and the IL-7 signaling pathway. B and T cell development relies on IL-7 signaling
for immunocompetence. The common lymphoid progenitors (CLPs) which differentiate into
all lymphoid lineages, including the B, T and NK cells, express IL-7R. These other subsets of
cells derived from the CLP have not been evaluated, but will likely be affected.
Immunodeficiency marked by increased susceptibility to and recurrent infections is
associated with abnormal B and T cell development. As cited earlier, numerous studies have
shown strong associations between arsenic exposure and increased susceptibility to infections
in children and adults. Occurrence of MMA+3 in urine of individuals exposed to arsenic is a
marker for cancer and other diseases. The most enzymatically active AS3MT genotypes are
associated with increased disease risk in humans exposed to arsenic (Pierce et al., 2013). Our
own lab’s work in human peripheral blood mononuclear cells (HPBMC) show that MMA+3
suppresses T cell activation at extremely low doses whereas As+3 does not (Burchiel et al.,
2014)
Also for the first time, the possibility and nature of interaction between As+3 and
DBC at very low levels to produce immunosuppression, was established even though our
understanding of the mechanisms involved are incomplete. It was expected that low levels of
As+3 in drinking water for 30 days may be toxic to the general BM populations, and this was
probably shown by the dose-dependent decrease in BM cellularity observed post exposure
(Table 2.1). However, the selective toxicity to the lymphoid progenitors over the myeloid
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was unanticipated. It was this selectivity, and the fact that the hematopoietic and
mesenchymal stem cell markers remained unchanged, that provided the clue to investigate
the lymphoid lineage-specific signaling as a possible mechanism.
Using mice as the in vivo model, mice primary BM cells, and 2E8 cell line as the in
vitro models, this study considered the two most ubiquitous environmental pollutants: arsenic
and PAHs at extremely low levels and physiologically applicable route of exposure. It also
considered the developing immune cells in their vital function of immune response. The
observations made here are important and revealed what could be occurring in the immune
system, even when there is no apparent disease. It could help focus attention to caring for the
immune function, especially when addressing As+3 and PAH- associated diseases. Although
the presence or lack of AS3MT in mouse BM myeloid and lymphoid cells has not been
established, the cells are exposed to these chemicals through the blood. Thus, the
observations made in this study are relevant.
Based on the observations made in this study, the following questions emerge that might
be important for follow-up studies:


At what specific step in lymphoid progenitor stem cell commitment do As+3/MMA+3
act?
 Possible Study: Evaluate the Lin/cKit/Sca-1 profile of BM immune cell
progenitors from low dose, long-term arsenite– exposed mice



Why are lymphoid cells more sensitive than many other cell types to arsenic
exposures? Do they have altered transporters for uptake and export that cause the
intracellular levels to be higher than other cells?
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 Possible Study: Determine absolute arsenic levels in selected cells in vivo and
in vitro.
 Possible Study: Evaluate the aquaglyceroporins (AQP7, mostly AQP9), a
major As+3 passive water importer, for expression and activity in BM myeloid
and lymphoid cells (Liu et al., 2002).
 Possible Study: Evaluate expression and activity of various exporters of
arsenic in lymphoid and myeloid cells, especially the ABC family of
exporters; Vernhet et al., (2011) have shown that blockade of MDR1
potentiates arsenic toxicity.
 Possible Study: Examine the role of AS3MT in lymphoid and myeloid BM
cells using AS3MT null mice (Chen et al., 2008) compared to wild type.


Why are only low doses or PAHs (DBC) associated with synergistic suppression of
As+3 and MMA+3 in murine bone marrow cells
 Possible Study: Study the influence of As+3 on DBC metabolism and
activation of CYP1B1
 Possible Study: Examine the effects and interactions of As+3/MMA+3 with
PAHs at the specific target protein or peptide level (e.g., STAT5, PARP,
XPA).
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LIST OF ABREVIATIONS
AAALAC Association for Assessment and Accreditation of Laboratory Animal Care
Ab Antibody
Ag Antigen
ANOVA Analysis of Variance
AO/PI Acridine Orange/Propidium Iodide
APL Acute Promyelocytic Leukemia
APC Accessory photosynthesis Pigment of the Cyanobacteria
AKR Alphaketoreductase
AQP Aquaglyceroporin
As+3 Arsenite
As+5 Arsenate
AS3MT Arsenite methyltransferase
ASTDR Agency for Toxic Substances and Disease Registry
ATCC American Type Culture Collection
ATM Ataxia Telangiectasia Mutated protein
ATR Ataxia Telangiectasia and Rad3-related protein
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BaP Benzo[a]pyrene
2-ME Betamercaptoethanol
BCA Bicinchoninic Acid
BM Bone Marrow
Ca2+ Calcium ion
CD Cluster of Differentiation
CFC Colony Forming Cell
CFU-B Colony Forming Unit for B cells
CFU-GM Colony Forming Unit for GM cells
CIS Cytokine Inducible SH2 –containing protein
CYP Cytochrome P450
CYP1 Cytochrome P450 1
CYP1B1 Cytochrome P450 1B1
cDNA copy Deoxyribonucleic acid
CLP Common Lymphoid Progenitors
CMP Common Myeloid Progenitors
DBC Dibenzo[def,p]chrysene
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DBC-dG Dibenzo[def,p]chrysene- deoxy Guanine adduct
DBC-dA Dibenzo[def,p]chrysene- deoxy Adenine adduct
DC Dendritic Cell
DMBA 7, 12-dimethylbenz[a]anthracene
DPBS Dulbecco’s Phosphate Buffered Saline
DPBS- Dulbecco’s Phosphate Buffered Saline without calcium and magnesium
EBF Early B cell Factor
EPO Erythropoietin
FITC Fluorescein Isothiocyanate
FSC Forward Scatter
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase
GF Granulocyte Factor
GM-CSF Granulocyte Monocyte- Cell Stimulating Factor
HBSS Hanks Balanced Salt Solution
HPBMC Human Peripheral Blood Mononuclear Cell
HSC Hematopoietic Stem Cell
IAUCC Institutional Animal Care and Use Committee
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HRP Horse Radish Peroxidase
IgG Immunoglobulin G
IL Interleukin
IL-7R Ilterleukin-7 receptor
IL-7Rα Interleukin 7 receptor alpha
IL-7Rγc Interleukin 7 receptor gamma chain
JAK Janus Kinase
kD Kilo Dalton
Mac Macrophage
MCL Maximum Contaminant Level
MDR1 Multi Drug Resistance gene 1
mEH microsomal Epoxide Hydrolase
Mg2+ Magnesium
mg/kg milligram per kilogram
µl microliter
MMA+3 Monomethylarsonous acid
mRNA messenger Ribonucleic acid
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NK Natural Killer cell
ng nanogram
ng/ml nanogram per milliliter
PAHs Polycyclic Aromatic Hydrocarbons
Pan NK Phenotypic Abnormality marker for NK cell
PARP Poly(ADP)ribose
PAX5 Paired Box-containing transcription factor 5
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PE Phycoerythrin
PerCP Peridinin-Chlorophyll-Protein
PFC Plaque Forming Cell
PI Propidium Iodide
PIAS Protein Inhibitors of Activated STATs
ppb parts per billion
pSTAT5 phosphorylated STAT5
PTP Phosphotyrosine Phosphatases
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pJAK1 phosphorylated JAK 1
qRT-PCR Quantitative Real Time Polymerase Chain Reaction
RPMI Roswell Park Memorial Institute
RIPA Radioimmunoprecipitation Assay
ROS Reactive Oxygen Species
SAM S-Adenosyl Methionine
SAHC S-Adenosyl Homocysteine
SDS Sodium DodesylSulphate
SH Sulfhydryl group
SRBC Sheep red blood cells
STAT5 Signal Tranducer and Activator of Transcription 5
TDAR T-Dependent Antibody Responses
Tyr Tyrosine
ZFPs Zinc Finger Proteins
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